Iminium Induced Cascade Cyclizations: Access to

Dihydroisoquinolinium (DHIQ) Salts, highly substituted Oxazoles, Furocoumarins and Pyridoxazoles by Babu, Venkata Nagarjuna & D S, Sharada
Iminium Induced Cascade Cyclizations: Access to 
Dihydroisoquinolinium (DHIQ) Salts, highly 
substituted Oxazoles, Furocoumarins and 
Pyridoxazoles 
 
 
Venkata Nagarjuna Babu 
 
 
A Dissertation Submitted to 
Indian Institute of Technology Hyderabad 
In Partial Fulfillment of the Requirements for 
The Degree of Doctor of Philosophy 
 
 
 
 
 
 
Department of Chemistry 
 
 
May 2019 
 
Declaration 
I declare that this written submission represents my ideas in my own words, and where others 
ideas or words have been included, I have adequately cited and referenced the original 
sources. I also declare that I have adhered to all principles of academic honesty and integrity 
and have not misrepresented or fabricated or falsified any idea/data/fact/source in my 
submission. I understand that any violation of the above will be a cause for disciplinary 
action by the Institute and can also evoke penal action from the sources that have thus not 
been properly cited, or from whom proper permission has not been taken when needed. 
 
 
 
_________________________ 
(Signature) 
 
Venkata Nagarjuna Babu 
  
CY14RESCH01007
  
  
 
-Dedicated to- 
 
 
 
My Beloved Family & 
My Supervisor 
Dr. D. S. Sharada 
  
 
CONTENTS 
Acknowledgements         i 
Abstracts          vi 
Abbreviations                   xxi 
CHAPTER 1:  
Introduction 
1.1 Reactivity of isocyanides       1 
1.2 Isomeric forms of isocyanide                  1 
1.3 Synthetic applications of Isocyanides                 3 
1.4 2-(2-bromoethyl)benzaldehyde and its Synthetic Applications  5 
1.5 N-Acyliminium ions and its applications     5 
1.6 Oxazoles and Furocoumarins importance and applications              7 
1.7 References         9 
CHAPTER 2: Transition-Metal-Free Cyclic Iminium Induced One-pot Double 
Annulation Cascade: Direct Access to Dihydroisoquinolinium (DHIQ) based 
Privileged Scaffolds 
2.1 Introduction                   11 
2.1.1 Importance of Isoquinolinium based Privileged Scaffolds                11 
2.2 Background                              12 
2.2.1. Selective Methods for Isoquinolinium and Imidazolium salts          12 
2.2.2. Multicomponent reactions (MCRs)                 17 
2.2.3. Isocyanides in [4+1] cycloadditon reactions              18 
2.2.4. Groebke-Blackburn-Bienayme (GBB) Reaction             18 
2.2.5. Sustainable Methods: Solvent-Free and Catalyst-Free Reactions     19 
     2.3  Results and Discussion                   20 
      2.4  Conclusions                   27 
2.5  Experimental Section                  27 
     2.6  References                   64 
CHAPTER 3: An Exocyclic N-Acyliminium ion (NAI) Cyclization: Access to 
Fully Substituted Oxazoles and Furocoumarins 
3.1 Introduction                              67 
3.1.1 Reactivity of N-Acyliminium ions (NAI’s)             67 
3.1.2 Types of N-Acyliminium ions              68 
3.2 Background                   69 
3.2.1 Selective Methods for Oxazoles synthesis             69 
3.2.2 Selective Methods for Furocoumarin synthesis            72 
3.3 Results and Discussion                 75 
3.4 Conclusions                   85 
3.5 Experimental Section                  86 
3.6 References                 138 
Graphical Abstract          
Curriculum Vitae and List of Publications 
ii 
 
 
 
ACKNOWLEDGEMENTS 
First, I would like to thank God for affording me the ability and opportunity 
to achieve my dreams satisfactorily, which would have been difficult without his 
blessings. 
It also gives me immense pleasure to acknowledge my supervisor Dr. D. S. 
Sharada, for giving me an opportunity to work in her research group. Her unending 
support, persistent questioning of results, suggestions and discussions provided me 
an extreme motivation throughout this work. I am eternally thankful her all the time 
for her valuable guidance and encouragement during my research in the lab.  
 
I would like to thank former Head of the Department and Dean of 
Academics Prof. F. A. Khan and Prof. G. Satyanarayana, Dr. A. K. Mishra, and 
Dr. K. V. Rao for their suggestions and agreement to be part of the doctoral thesis 
committee. 
 
I sincerely thank Head of the Department Prof. M. Deepa and other 
faculties of the Department of Chemistry, IIT Hyderabad. 
 
I gratefully acknowledge the Indian Institute of Technology Hyderabad 
for providing the required facilities and the University Grants Commission (UGC) 
New Delhi, India for the financial support. 
 
I take pride to acknowledge Prof. M. Bakthadoss (PCU, Pondicherry) for 
his valuable support towards the up gradation from JRF to SRF as well as for his 
suggestions and encouragement during our every meet at IIT Hyderabad. 
 
I thank Prof. Ch. Subrahmanyam, Prof. Prabu Sankar, Prof. T. K. 
Panda, Dr. Bhabani Shankar Mallik, Dr. S. K. Martha, Dr. S. Maji, Dr. S. 
iii 
 
 
Maity and Dr. Jay Prakash    and faculty members for their co-operation and 
providing facilities in IITH. 
 
I feel very much happy to thank my M.Sc. teachers Pandla Brammaiah sir, 
Sharath sir, Rangaratnam sir, Umapathi sir and Venkata ramana sir for their 
valuable suggestions and encouragement.   
 
I would like to thank my department friends Dr. Manoj Reddy, Dr. A. Gopi 
Krishna Reddy, Dr. Jonnada Krishna, Dr. Kotalanka Ravikumar, Dr. Krishna 
Murthy, Dr. Katam Srinivas, Dr. Pendyala Naresh Kumar, Dr. Niharika, Dr. 
Suchand Basuli, Mr. Ramesh, Mr. Murugan, Ms. Shravanthi madam, Dr. 
Raveendra Babu, Mr. Narender Reddy, Dr. Mosim, Mr. Altaf, Mr. Tapan 
Kumar Jena, Mr. K. Sriniwas, Mr. Shivaji, Dr. Nagababu Chatla, Mr. K. 
Ramesh, Mr. Raju, Mr. Moulali, Dr. A. Srinivas, Ms. Jayeeta, Mr. Harinath, 
Mr. Suman Das, Ms. Indrani, Mr. Ravi Kumar, Dr. Krishna Murthy, Dr. 
Laxman, Mr. Laxminarayana, Mr. Subramanniyam, Ms. Aparajita, Ms. 
Radha, Mr. Ramesh, Dr. Krishna Kumar, Mr. Naresh, Dr. Suhag for their 
cheerful and company, and Mr. Md. Samiuddin for recording NMR spectra, Mr. 
L. Mahendar, Mr. Md. Samiuddin, Mr. Altaf for recording the HR-MS, and Dr. 
K. Ravi Kumar, Dr. Anga Srinivas, Mr. Suman, Mr. Gembali Raju and Mr. 
Harinath for X-Ray diffractometer measurements and analysis of single crystal 
samples. I sincerely thank to technical and non-teaching staff of IIT Hyderabad, 
in particular Mr. Ashok, Mr. Ramana Babu and Mr. Vijay Kumar for DSC 
measurements. 
 
I also would like to thank administration department members Mr. Jameel, 
Mr. M. Kumar Das, Mr. Sadique, Mr. Mosim, Mr. Srinivas, Mr. Rajesh, Mr. 
Sastry, Mr. Vijay kumar, and Mr. Praveen for their support. 
 
iv 
 
 
I sincerely thank my lab colleagues Dr. S. Vidyacharan, Dr. Anand Shinde 
Mr. Sagar A., Ms. Srilaxmi, Mr. Mayur, Mr. Srideep, Mr. Narender Reddy 
Katta, Dr. Ashok, Dr. Suman, Mr. N. Sabarinathan, Ms. Sonali biswal for their 
help and support, and having tolerated my moods during my  Ph.D. and our previous 
master students worked in our lab Mr. Kuntal, Ms. Amreen, Mr. Ajoy, Ms. 
Mamata Ojha, Mr. Soumyadeep, Mr. Pradeep Maji, Mr. Sitansu Muni, Mr. 
Vishal, Mr. Sakshey, Mr. Shrutarshi  and my special appreciations goes to Ms. 
Ruma Ghosh, Ms. Diksha Malik, Mr. Srikanth and Mr. Narender Reddy Katta 
(Thamudu) for their help and assistance during my Ph. D.  
 
My lovely thanks to my intern students Ms. Greeshma Suresh, Ms. 
Reshma Sanal, Ms. Keerthi Vijayan, Ms. Reshma Ramesh, Ms. Amitha John, 
Ms. Sherya, Ms. Sandra, Ms. Jothi, Ms. Kaviya, Mr. Srikanth, Ms. Harika, Mr. 
Narender Reddy Katta, Mr. Heleena, Mr. Latha, Ms. Lydia, Ms. Rohini, Mr. 
Akil, Ms. Anusha, Ms. Sawthi who has helped to accelerate my progress and made 
happy environment in our research lab. 
 
I would like to thank to Vedic science club (ISKCON) and My special 
thanks to Mukunda Prabhu and Brajabandu Prabhu, Venugopal for Moral and 
Spiritual Support having encouraged me to pursue my dreams.  
 
No words can ever express the feeling that I have for my parents 
Venkateshwar Rao, Laxmi Kumari, the sacrifices they have made for me with 
responsibility at every moment of my life, it cannot be comparable with the any 
valuable things in the world. I am very much grateful to my sister Supriya, my 
brother in-law (Rambabu), Son in Law (Pavan), and my grandma (Laxmi 
Kantam), (Grandpaa Subramanyam Late) for their love, affection and having 
encouraged me to pursue my dreams.  
Finally, I also would like to thank everyone those who helped me directly or 
indirectly by mean of any ways to pursue my dreams. 
                                                                                            Venkata Nagarjuna Babu. 
v 
 
 
 
ABSTRACT 
Introduction 
The demand for sustainable and green chemistry has inspired chemists to 
hunt for efficient and economic ways to construct chemical bonds in organic 
synthesis. In particular, C-C, C-O and C-N bonds formation is a central aspect in 
synthetic chemistry. On the other hand, C-H bonds are ubiquitous in organic 
molecules. Therefore, the direct functionalization of C-H to C-C, C-O and C-N 
bonds becomes one of the most valuable and straightforward methods for the 
synthesis of complex structures.  
Sustainability has become one of the important scientific challenges 
nowadays, due to environmental, health and societal concerns. Due to this, there is a 
need for developing facile, efficient, and non-polluting synthetic procedures to 
reduce the use of organic solvents and toxic reagents. One such approach, which 
involves green and sustainable chemistry, drives towards pollution prevention and 
environmental protection, and is now gaining importance. Which mainly involves 
designing chemical products and processes that reduce or eliminate the use of 
hazardous substances, volatile organic compounds, generation of waste materials, 
by-product formation and unnecessary derivatization (like blocking, 
protecting/deprotecting) etc. 
One of the strategies widely implemented is the development of alternative 
sustainable routes involves catalyst-free and solvent-free reactions (CFR & SFR) 
which have gained importance recently. These approaches have several advantages 
over the conventional organic synthetic methods, like (a) reduced pollutant 
production, (b) reduced use or elimination of toxic and hazardous chemicals, (c) 
operational simplicity, (d) decreasing the reaction time (under SFR), (e) formation 
of pure products which avoids tedious purifications, (f) high yields, (g) reduced cost 
and many more.  
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Due to the various advantages of solvent-free and catalyst-free reactions, 
from the past decades tremendous efforts have been made by several groups for the 
synthesis of heterocyclic molecules. 
Accordingly, we have developed the green protocols particularly solvent-
free, catalyst-free techniques and designed acid catalyzed cyclizations for making 
Dihydroisoquinolinium (DHIQ) Salts, highly substituted Oxazoles, Furocoumarins 
and Pyridoxazoles. 
PROPOSED CONTENTS OF THE THESIS: 
 
Chapter I: Introduction 
Chapter II: Metal-Free Cyclic Iminium Induced One-pot Double Annulation 
Cascade: Access to Dihydroisoquinolinium (DHIQ) Salts 
 
Chapter III: An Exocyclic N-Acyliminium ion (NAI) Cyclization: Access to Fully 
Substituted Oxazoles and Furocoumarins    
Description of the research work 
Chapter I: Introduction 
In this chapter, we have described the introduction about reactivity of 
isocyanides, and their synthetic applications, importance of 2-(2-
bromoethyl)benzaldehyde. Further we described about N-Acyliminium ions and its 
applications, Oxazoles and Furocoumarins importance and their applications. 
  
Chapter II: Metal-Free Cyclic Iminium Induced One-pot Double Annulation 
Cascade: Access to Dihydroisoquinolinium (DHIQ) Salts 
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Scheme 1 Metal-Free Double Annulation Cascade: Access to 
Dihydroisoquinolinium (DHIQ) Salts 
 
 The ubiquity of the isoquinoline (IQ) framework in biologically active 
natural products, besides its applications as pharmaceuticals, functional 
organic materials and ligands for asymmetric catalysis have turned the 
attention of synthetic organic chemists in recent years. Among IQ derivatives, 
fused IQ salts are naturally occurring alkaloids and promising lead structures 
in drug discovery. The iminium moiety in these derivatives was found to be 
essential for significant biological activities. Though several reports have been 
documented for the synthesis of these derivatives, most of the methods  
involve starting material with preformed IQ skeleton, expensive metal 
catalysts, multiple steps, lack of diversity, scalability, and tedious routes to 
access starting material. Beside isoquinoline motif dihydroisoquinolinium 
(DHIQ) ion and pyrido-imidazo[5,1-a]isoquinolinium ion also form an 
important core structure of natural products and pharmaceuticals (Figure 1).  
 
 Our interests in the development of metal-free protocols for the synthesis of 
heterocyclic scaffolds, persuaded us to design a strategy for the synthesis of 
azaheterocycles.   
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Figure 1 Representative examples of bioactive molecules and natural products 
The versatility of 2-(2-bromoethyl)benzaldehyde (1a) as a promising 
bifunctional reactant in various organic transformations has been well documented, 
especially leading to tetrahydroisoquinoline (THIQ) motifs based natural products 
and their analogues (Figure 2). 
 
Figure 2 
 To test the above hypothesis, a preliminary reaction of equimolar mixture 
of 2-(2-bromoethyl)benzaldehyde 1a, 2-aminopyridine 2a and 
cyclohexylisocyanide 3a was performed at ambient temperature (35 °C) in 
ix 
 
 
methanol for 10h, which afforded the desired product 4aaa, albeit in low yield 
(Table 1, entry 1). Encouraged by this result, and to further explore, we 
increased the temperatures which resulted in improvement of yields up to 64% 
Table 1 Double annulation cascade to pyridoimidazo-DHIQ salt 4aaaa,b 
 
entr
y 
solvent 
temp 
(°C) 
time 
(h) 
yield 
(%) 
1 MeOH 35 10 10 
2 MeOH 50 20 20 
3 MeOH 70 22 54 
4 MeOH 90 20 64 
5 EtOH 100 20 67 
6 H2O 100 20 0 
7 DCE 100 23 40 
8 DCM 50 14 32 
9 CH3CN 90 21 43 
10 THF 90 14 35 
11 1,4 
dioxane 
110 10 55 
12 No 
solvent 
rt 10 Trace 
13 No 
solvent 
50 20 40 
14 No 
solvent 
60 2 66 
15 No 
solvent 
80 10 
min  
91 
16 No 90 10 min 70 
x 
 
 
solvent 
17 No 
solvent 
100 10 min 66 
a Reaction conditions: 1a (0.23 mmol), 2a (0.23 mmol) and 3a (0.23 mmol). b Yield of isolated 
product after column chromatography. 
 
 (Table 1, entries 2-4). Moreover, in protic and aprotic polar solvents, even 
after continuing the reaction for long hours the starting materials were not 
completely consumed (Table 1, entries 5-11).  
 When we perform the reaction under solvent-free conditions. Not 
surprisingly, higher temperatures resulted in improved yields of the products 
with drastic reduction in time (Table 1, entries 13-15). However, beyond 80 
°C we have seen drop in the yields (Table 1, entries 16 and 17), which could 
be due to decomposition of reaction mixture.  
 With the reaction at 80 °C as optimized condition (Table 1, entry 15) 
for double annulation cascade (DAC) in hand we planned to evaluate the scope of 
our strategy. In this direction, we extended it to various aminoazines 2 and 
isocyanides 3, keeping the aldehyde 1 component constant to obtain corresponding 
pyridoimidazoisoquinolinium derivatives (Table 2, 4aaa-4ace) in good to excellent 
yields. 
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Table 2 Synthesis of pyridoimidazo-DHIQ scaffolds a,b 
 
 
 
a Reactions were performed with 1 (0.23 mmol), 2 (0.23 mmol) and 3 (0.23 mmol) at 
80 oC. b Yield of isolated product after column chromatography. 
 Our pursuit for diversity oriented synthesis (DOS) impelled us to examine 
diversity of our present strategy. Accordingly, we probed with structurally and 
skeletally different aminoazines, which to our delight provided interesting and 
diverse tetra- and pentacyclic IQ scaffolds (Table 3). When we have used 
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other heterocyclic aminoazines we have not observed any detrimental effect 
on reaction outcome. 
Table 3 Synthesis of skeletally diverse DHIQ scaffolds a,b  
 
 
a Reactions were performed with 1 (0.23 mmol), 2 (0.23 mmol) and 3 (0.23 mmol) at 
80 oC.  b Yield of isolated product after column chromatography.  
 
we have developed a mild, efficient and metal-free protocol for the 
synthesis of fused IQ derivatives under solvent-free conditions. We have 
demonstrated an unprecedented cyclic iminium induced GBB leading to 
construction of two privileged heterocyclic rings in one-pot. This double annulation 
cascade provided pyridoimidazo-DHIQs in excellent yields by easy isolation 
without tedious workup. In addition, readily accessible starting material, remarkably 
short reaction time, simplicity in operation, scope of skeletal diversity, H2O as sole 
byproduct.  
Chapter III: An Exocyclic N-Acyliminium ion (NAI) Cyclization: Access to Fully 
Substituted Oxazoles and Furocoumarins    
N-acyliminium ions (NAIs) are well recognized as potent or highly reactive 
intermediates in C-C and C-heteroatom bond forming reactions, and extensively 
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explored for the synthesis of diverse natural-products and bioactive molecules due to 
their highly electrophilic nature. Chemists have developed N-acyl iminium ion 
based biomimetic approaches for the synthesis of various alkaloids inspired by 
nature’s design principles. Owing to their significant importance, chemists have 
been paid substantial attention to the development of a variety of NAI precursors 
(Figure 3). Among them, pyrrolidine based NAI ion precursors have obtained a 
dominant position for enabling powerful access to the generation of cyclic NAIs 
particularly endo-cyclic by the treatment of Brønsted acid or Lewis acid, and which 
are mainly limited to intramolecular cyclization reactions. However, the 
development of a direct route to access NAI precursors and their further 
transformations toward diverse scaffolds in a single pot is a daunting challenge. The 
reason is the formation of NAI ion species prerequisite is a good leaving group at 
the α-position to the nitrogen atom. In order to bring leaving groups at the desired 
position in substrates involves multistep syntheses and which are highly difficult to 
operate in single pot. These challenges led us to examine a direct synthetic route to 
access NAI precursors and their further efficient transformations through a cascade 
process. The acid catalyzed reactions of NAI salts well explored in the literature, 
these transformations mainly involved the generation of cationic NAI ions in the 
presence of excess strong acid. As per the literature survey, these type of conditions 
lead to the formation of dicationic species are called super electrophiles, which can 
be explored in further transformations with suitable nucleophiles. 
 
Figure 3. Literature known NAIs and our designed NAI 
Recently, we have developed an iminium induced one-pot double annulation 
cascade strategy for the synthesis of dihydroisoquinolinium salts. Inspired by this 
work and our continuing interest in the development of metal-free and green 
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strategies for the synthesis of biologically important heterocyclic compounds, 
herein, we report a novel super-acid-promoted tandem cyclization strategy to 
synthesize diversified fully substituted Oxazoles and Furocoumarins from readily 
available starting materials via insituly generated exocyclic NAI precursor in one 
pot. The development of a straightforward method to access the above mentioned 
privileged scaffolds via insitu generation of NAI precursors would be of great 
importance.    
 
Scheme 2 Synthesis of Fully Substituted Oxazoles and Furocoumarins    
Having this catalyst and solvent-free conditions for NAI precursor A in hand, 
our attention was turned towards the utilization of it for the synthesis of Biologically 
active molecules. 
firstly, we hypothesized to synthesize fully substituted Oxazole derivatives 
by using nitriles through 3+2 cycloaddition under Metal-free conditions.      
Due to Oxazole derivatives found in a wide range of pharmaceuticals, natural 
products and agrochemicals. Among these Oxazole derivatives serve as an important 
chiral sources or ligands in asymmetric transformations. 
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Accordingly, to test our hypothesis, first we generated the NAI precursor A 
by the reaction of phenylglyoxal 1a with 2-pyrrolidinone 2a under standard 
conditions, which could subsequently use as the model substrate without isolation. 
Among the various Brønsted acids screened, only triflic acid effectively 
promoted the desired product. In order to evaluate the effects of acidity we screened 
with different equivalents of triflic acid under various temperatures, finally, 5.0 
equiv of triflic acid was found to be effective at 130 °C to afford the desired product 
4a in excellent yield 91%. 
After having the optimized conditions in hand, we have explored the 
substrate scope of the present protocol (Table 3).  Arylglyoxals bearing electron-
neutral (4a, 4b & 4c), electron-rich (4d) and electron-deficient (4e-4k) substituents 
were smoothly converted to the corresponding oxazoles with moderate to very good 
yields. Interestingly, halo-substituted (4j-4n) arylglyoxals were also found to furnish 
the desired products with good yields (66-86%), which would provide possibilities 
for further functionalization. Pleasingly, 2-oxazolidinone in place of 2-pyrrolidinone 
were also found to furnish the desired products with very good yields (4g, 4h, 4m & 
4n).  
Table 4. Scope of the synthesis of various fully substituted oxazolesa 
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aReaction conditions: 1st step: 1a (1.0 mmol), 2a (1.1 mmol), 80 °C, 10-20 min, 2nd 
step: DCE dry solvent (0.25 M), 3a (1.1 mmol), TfOH (5 mmol), 130 °C, for 2-3 h.  
b Isolated yields, after column chromatography.   
Next we checked the reactivity of strong electron withdrawing group (-NO2) 
in the 4th position of arylglyoxal unit (Table 4, 4s & 4t), unfortunately in both the 
examples we got the both oxazole and bisamide products, after prolonged reaction 
hours also we didn’t observe the complete conversion of bisamide to oxazole 
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products. We achieved the less oxazole product yields in both 4s & 4t cases (26% & 
32%).  
 In order to expand the molecular library of polyfunctional oxazole 
derivatives, we extended it to the heteroaryl nitriles, like 2-cyanopyridines, for the 
synthesis of valuable bis-hetero cycles those are pyrid-oxazoles skeletons as shown 
in table 3. In this transformations, 2-cyanopyridine is reacted smoothly with NAI 
intermediates generated from arylglyoxals and 2-oxazolidinone or 2-pyrrolidinone to 
afford the desired products from good to excellent yields (Table 4, 4o-4r).  
After successfully synthesis of fully substituted Oxazoles, further our 
attention was turned towards the synthesis of Furocoumarins, owing to the wide 
spectrum of biological activities, agrochemicals and synthetic applications, have 
triggered substantial interest for their synthesis. Accordingly, the new protocol was 
further demonstrated by using 4-hydroxy-2H-chromen-2-one as carbon-nucleophile 
(Table 5). Arylglyoxals with electron-neutral (7a & 7g), electron rich (7d & 7e) and 
electron-deficient (7b, 7h, 7f & 7c) substituents were smoothly transformed into the 
corresponding privileged Furocoumarine under the optimized conditions with very 
good yields (Table 5).  
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Table 5. Scope of the Synthesis of Furocoumarins 
 
aReaction conditions: 1st step: 1 (1.0 mmol), 2 (1.1 mmol), 80 °C, 10-20 
min, 2nd step: DCE dry solvent (0.25 M), 6 (1.1 mmol), TfOH (5 mmol), 80 °C, 1-2 
h.  b Isolated yields, after column chromatography. 
To gain insight into the reaction mechanism, preliminary control experiments 
were conducted. When the reaction was performed in the absence of acid, no desired 
product was formed, indicating that the presence of acid is crucial for this reaction 
(Scheme 3a).  Since the present reaction requires excess acid to effect the 
transformations (standard conditions), we hypothesized that the reaction might be 
proceed through proto-solvation of N-acyliminium ion B (Scheme 3b). Accordingly, 
we have performed the reaction with weak nucleophile i.e. benzene instead of 
acetonitrile 3a. To our delight, we could have isolated the benzene trapped product 
C with 80% yield.  
xix 
 
 
This result suggested that a proto-solvated iminium intermediate B was most 
likely involved in this reaction. To know further possible intermediates as per our 
observations during optimization of reaction conditions, we assumed that either 
bisamide or nitrelium ion may be the reaction intermediates after attacking of nitrile 
3a to intermediate B to afford the oxazole 4a. Accordingly, we have subjected the 
bisamide 5a to standard conditions, which resulted in oxazole 4a with excellent 
yield as we expected (Scheme 3c).    
Scheme 3. Mechanistic Experiments. 
 
Based on the above observed products and previous literature reports,3a, 4 a 
plausible mechanism was proposed for the present reaction (Scheme 4). Initially the 
NAI precursor A would form the iminium intermediate B under acidic conditions. 
Then cyclization was occur by two conceivable paths: In path a, acetonitrile would 
attack proto solvated iminium intermediate B to afford nitrilium ion I, which then 
would neutralized by the adjacent carbonyl oxygen to furnish the final product 4a. In 
path b, the nitrilium ion I would be neutralized by the water molecule to form the 
bisamide 5a, which would further undergo dehydration -cyclization to furnish the 
final product 4a.  
After having synthesized compounds in hand, we were keen to study the 
UV-visible and fluorescence characteristics of chosen Pyrid-oxazoles and 
Furocoumarins. The UV-visible spectra of compounds 4r, 4p, 4q & 4o in ethanol 
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(EtOH) exhibited maximum absorption wavelength (λmax) at 320 nm. The 
fluorescence spectra of Pyrid-oxazole compounds showed emission wavelength 
(λem) at 414-464 nm. 
Similarly, we have also recorded the UV-visible and fluorescence spectra of 
Furocoumarins (7a-7h) in EtOH. The UV-visible spectra of compounds 7a-7h 
(Figure 3d) exhibited maximum absorption wavelengths at 205-210 nm. The 
fluorescence properties of the compounds 7a-7h (Figure 3c) displayed emission 
wavelength (λem) at 396-449 nm. 
In summary, we have described a concise, one-pot route to Oxazoles and 
Furocoumarins through N-acyliminium ion as a key intermediate. The key step in 
this transformation involves insitu generation of NAI precursor under catalyst and 
solvent free conditions, and their further transformations promoted by superacid in 
the same pot. The experimental evidence for the involvement of proto-solvated 
novel exocyclic N-acyliminium ion in superacid promoted reaction has been 
presented. We have also investigated the photophysical properties of Furocoumarins 
and Pyrid-oxazole derivatives, and these studies reveal that possible applications for 
the discovery of highly fluorescent probes.  
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DCM       Dichloromethane 
dd       Doublet of doublet 
ddd       Doublet of doublet of doublet 
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DMF       Dimethylformamide 
DMSO       Dimethyl sulfoxide 
dt       Doublet of triplet 
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Me       Methyl 
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Mp        Melting point  
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rt       Room temperature 
s       Singlet (spectral) 
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CHAPTER 1 
Introduction 
 
1.1. Reactivity of isocyanides 
Isocyanides are also called as isonitriles or carbylamines and they are the most 
valuable functional group in organic chemistry.1 Isocyanide is a useful synthetic building 
block, owing to the unusual reactivity of terminal carbon center due to its ambiphilic nature 
which participates with various electrophiles and nucleophiles. In addition, isocyanides are 
isoelectronic with CO, due to its intrinsic property these compounds also show high affinity 
towards organometallic reagents and in recent years, radical reactions of isocyanides have 
found great use in various organic transformations.2  
Isocyanides due to its peculiar intrinsic ambiphilic property and its affinity towards 
metal have been widely explored as C1 synthons for the synthesis of diverse nitrogen 
heterocycles of medicinal and biological relevance. Further, isocyanides have been 
successfully employed as C1 synthons in cycloaddition reactions.3 On the other hand, the 
unique affinity of isocyanide towards metals has been explored with transition metals such as 
palladium, cobalt and nickel catalyzed insertions between various bisnucleophiles in recent 
times.4  
1.2. Isomeric forms of isocyanide 
Isocyanides exists in two isomeric structures viz.  
(a) zwitterion form  
(b) exhibit like a carbene (Scheme 1) 
                  
Scheme 1. Resonance structures of isocyanides 
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“Xanthocillicin” is the first reported natural product from marine sources in 1956 by 
Hagedorn and Toenjes. 
Isocyanide was first discovered by Lieke5 in 1859 by the treatment of silver cyanide 
with allyl iodides (Scheme 2). 
 
Scheme 2. Lieke’s synthesis of isocyanide  
In 1867, Hoffmnn6 developed a new protocol for the synthesis of isocyanide by the 
condensation of a primary amine with dichlorocarbene, produced insituly by heating 
chloroform with potassium hydroxide. Nevertheless, this method has various drawbacks like 
reproducibility, low yield and difficulty of separation of isocyanides from amines (Scheme 
3).  
 
Scheme 3. Hoffmann’s synthesis of isocyanide (Carbylamine method) 
Later, Ivar Ugi after tremendous efforts discovered a convenient method for the 
formation of isocyanide via the dehydration of N-monosubstituted formamide which could be 
obtained from primary amines and methyl formate or formic acid (Scheme 4).7  
 
Scheme 4. Ugi’s synthesis of isocyanide 
Commonly, isocyanides are synthesized by the dehydration of formamides. The 
formamide can be dehydrated with phosphorus oxychloride, toluene sulfonyl chloride, 
phosgene, diphosgene, or with the Burgess reagent in the presence of a base such as pyridine, 
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triethylamine and diisopropylethylamine (Scheme 5). Ugi made significant contributions by 
synthesizing more than 230 isocyanides.8 
 
Scheme 5. Dehydration of formamide using POCl3 
 
1.3. Synthetic applications of Isocyanides 
The unique reactivity nature of the isocyanides, diversity of bond forming processes, 
functional group tolerance, and the high levels of chemo-, regio-, and stereoselectivity have 
led to plethora of organic transformations like isocyanide based multicomponent reactions 
(IMCRs),7-9 e.g. Ugi and Passerini reactions (Scheme 6), co-cyclizations utilizing isocyanides 
as one carbon donor,10 (Scheme 7) transition-metal catalyzed insertions,11 and oligo- and 
polymerizations.12 
 
Scheme 6. The three-component Passerini and the four-component Ugi reaction 
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Scheme 7 
Cycloadditions have emerged as the most efficient chemical processes, combining 
atom economy, stereoselectivity, stereospecificity, and the ability to generate molecular 
complexity in a single step. [4+1] cycloaddition is among most powerful reactions in the 
arsenal of the synthetic chemists for the synthesis of five-membered rings owing to the 
ubiquity of five-membered carbo- and heterocyclic substructures in natural products. The 
formal [4+1] annulation involves a reaction between four atom conjugated system and C1 
source, providing an alternative and versatile approach to these compounds because of their 
distinct synthetic advantages and the immediate availability of the preliminary materials. 
An example of a formal [4+1]-cycloaddition of α, β-unsaturated carbonyl compound 
with isocyanide (Figure 1). 
 
Figure 1. Diverse dienes in isocyanide based formal [4+1] cycloadditions 
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Figure 2. Synthesis of diverse heterocycles using isocyanides in formal [4+1] cycloadditions. 
1.4. Synthetic applications of 2-(2-bromoethyl)benzaldehyde  
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Figure 3. Various approaches to THIQ motifs starting from 2-(2 bromoethyl)benzaldehyde 
The versatility of 2-(2-bromoethyl)benzaldehyde 14 as a promising bifunctional 
reactant in various organic transformations has been well documented by our group and 
others,13,14 especially leading to tetrahydroisoquinoline (THIQ) motifs based natural products 
and their analogues (Figure 3). However, utilization of 14 in the synthesis of fused 
dihydroisoquinolinium salts is not explored to date. Very recently, in our lab, we have 
documented some interesting cascade strategies employing 14 for the synthesis of skeletally 
diverse THIQ skeletons (Scheme 2).13  
 
1.5. N-Acyliminium ions and its applications 
N-acyliminium ions (NAIs) are well recognized as potent or highly reactive 
intermediates in C-C and C-heteroatom bond forming reactions, and extensively explored for 
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the synthesis of diverse natural-products and bioactive molecules15 (Figure 1) due to their 
highly electrophilic nature. 
 
Figure 4: Plethora of structurally diverse compounds prepared through the cyclization 
of N-acyliminium ions (Courtesy: Chem rev.)15a 
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1.6. Oxazoles and Furocoumarins importance and their applications 
Oxazoles are heterocyles containing nitrogen and oxygen atoms in the five-membered 
aromatic ring. They are known to bind to a variety of enzymes and receptors in the biological 
systems via various non-covalent bond interactions, and due to this it can able to display 
versatile biological activities. 
The related oxazole-based scaffolds such as oxazoles, isoxazoles, benzoxazoles, 
oxazolines, oxazolidones, oxadiazoles, and so on (Figure 5), are well known medicinal drugs 
and has been an extremely attractive topic, and numerous excellent biological properties have 
been acquired.16 
 
Figure 5: Oxazole-based scaffolds in medicinal chemistry 
Noticeably, a high number of oxazole compounds as clinical drugs or candidates have 
been frequently used for the treatment of many types of diseases, which have shown their 
high development value and have broad potential as medicinal agents.16 
Oxazole compounds are found to be useful as antifungal, antibacterial, antiviral, 
anticancer, anti-inflammatory, antitubercular, antiparasitic, analgesic, antidiabetic, anti-
obesitic, anti-neuropathic, antioxidative as well as other biological activities,16 and as 
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agrochemicals.17 Among these oxazole derivatives serve as important chiral ligands or source 
in asymmetric transformations. Furthermore, dihydrooxazoles can be easily transformed into 
other useful functional groups, such as carboxylic acids and amines (Figure 6).17 
 
Figure 6: Importance of Oxazole derivatives 
The coumarin ring is a key structural core unit for numerous natural products, 
synthetic pharmaceuticals, and a wide variety of biologically active compounds. Modified 
coumarin compounds are shown to exhibit a broad range of biological activities and also as 
potent anti-HIV agents and anticancer agents.18 
 Among them, furochromen-4-ones (furocoumarins), tricyclic systems in which a 
furan ring is fused to the chromen-2-one unit, are of particular interest since they exhibit 
potent biological and pharmacological activity.19 (Figure 7) 
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Figure 7: Importance of furocoumarins 
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CHAPTER 2 
Transition-Metal-Free Cyclic Iminium Induced  
One-pot Double Annulation Cascade: Direct Access  
to Dihydroisoquinolinium (DHIQ) based Privileged 
Scaffolds 
 
2.1. Introduction 
2.1.1 Importance of Isoquinolinium based Privileged Scaffolds 
 
The ubiquity of the isoquinoline (IQ) framework1 in biologically active natural 
products, besides its applications as pharmaceuticals, functional organic materials and ligands 
for asymmetric catalysis have turned the attention of synthetic organic chemists in recent 
years. Among IQ derivatives, fused IQ salts are naturally occurring alkaloids2 and promising 
lead structures in drug discovery.3  
 
    
Figure 1 Representative examples of bioactive molecules and natural products. 
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The iminium moiety in these derivatives was found to be essential for significant 
biological activities.4 Though several reports have been documented for the synthesis of these  
derivatives, most of the methods5 involve starting material with preformed IQ skeleton, 
expensive metal catalysts, multiple steps, lack of diversity, scalability, and tedious routes to 
access starting material. Beside isoquinoline motif dihydroisoquinolinium (DHIQ) ion and 
pyrido-imidazo[5,1 a]isoquinolinium ion also form an important core structure6 of natural 
products and pharmaceuticals (Figure 1), however, very few methods7 have been reported for 
DHIQ derivatives. 
 
2.2. Background 
2.2.1. Selective Methods for Isoquinolinium and Imidazolium salts 
Isoquinolinium cation is an important structural motif found in many naturally occurring 
compounds, which exhibit numerous important biological activities.8 They are also known as 
potential intermediates for the synthesis of many bioactive and heterocyclic compounds.9 
Owing to their broad application, several metal-mediated or catalyzed methods have been 
known for the synthesis of isoquinolinium salts.10 
The protoberberines represent a large class of alkaloids characterized by the 5,6-
dihydroisoquinolino[3,2-a]-isoquinolinium skeleton.11 The quaternary protoberberines 
together with their partially reduced analogues, the dihydro and the 
tetrahydroprotoberberines, are widely distributed in plants and more than a hundred 
representatives are known to date.12  
In particular, the permanently charged quaternary protoberberines possess pronounced 
biological activities, such as antimicrobial,13 anti-inflammatory,14 antimalarial,15 and 
antitumor.16 These activities have partly been attributed to their DNA intercalating 
capability17 as well as to their general electrophilic reactivity.18 
In 2015, Opatz et al. reported the synthesis of protoberberine alkaloids 
pseudoepiberberine and pseudopalmatine from readily available 1, 2, 3, 4-
tetrahydroisoquinoline-1-carbonitriles and 1, 2-bis(bromomethyl)arenes is developed. Here 
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the important reaction step was Stevens rearrangement of nitrile-stabilized ammonium ylides 
(Scheme 1).19 
 
 
Scheme 1 
In 2015, Cheng et al.20 reported a highly regioselective ruthenium-catalyzed synthesis 
of substituted isoquinolinium salts from the reaction of benzaldehydes, amines, and alkynes 
via C-H bond activation and annulation. The proposed mechanism is strongly supported by 
the isolation of a five-membered ruthenacycle and an intermediate organic compound 
(Scheme 2).    
 
Scheme 2 
Recently, transition-metal-catalyzed C–H bond activation reactions have played an 
important role in the formation of carbon–carbon and carbon–heteroatom bonds. In 
particular, Rh(III)-complexes have revealed great potential in the synthesis of various 
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heterocyclic and carbocyclic compounds through the C–H bond activation reactions. In this 
context, in 2015, Chien-Hong Cheng et al.21 reported the synthesis of various 1-substituted 
isoquinolinium salts from ketimines and alkynes via rhodium(III)-catalyzed C–H bond 
activation and annulation reaction.   
 
 
 
Scheme 3 
In 2013, Huang et, al.22 describes the synthesis of broad range of isoquinolinium salts. 
Here they disclosed a novel Rh/O2 catalytic system that is efficient for the oxidative coupling 
of 2-arylpyridines and alkynes (Scheme 4).   
 
Scheme 4 
In 2012, Shen et al. have developed an efficient approach to 
pyridoimidazoisoquinolinium compounds via Yb(OTf)3 /AgOTf catalyzed one-pot synthesis 
(Scheme 5).23 However, it involves use of expensive two metal catalysts, inaccessible starting 
material, lack of generality and lengthy synthetic steps.  
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Scheme 5 
 
 
In 2015, Li et al.24 describes the synthesis of fused isoquinolinium tetrafluoroborates 
by Rhodium catalyzed oxidative annulation of 2-phenylimidazo[1,2-a]pyridines with alkynes. 
Here, when AgOAc was used as an oxidant, this coupling afforded 5,6-disubstituted naphtho-
[1′,2′:4,5]imidazo[1,2-a]pyridines as a result of initial chelation assisted C-H activation at the 
benzene ring followed by rollover C-H activation at the heterocycle. In contrast, the reaction 
afforded a fused isoquinolinium as a result of C-C and C-N coupling while AgBF4 was 
employed as a co-oxidant (Scheme 6). 
 
Scheme 6 
Imidazo[5,1-a]isoquinolinium salts are used as orally effective blood sugar lowering 
agents in the treatment of diabetes. Several methods have been reported for the synthesis of 1-
aminoimidazo [5, 1-a]isoquinoline. In 2008, Shaabani et, al.25 reported the synthesis of 1-
Aminoimidazo [5, 1-a]isoquinolinium Salts, from various isocyanides with isoquinoline in 
the presence of various sulfonic acids.  
 
Scheme 7 
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Recently In 2018, Alireza et al.26 have synthesized and characterized a new class of 3-
(trifluoromethyl)-2H-imidazo[5,1-a]isoquinolinium chlorides under mild conditions, by the 
reaction of isoquinoline with trifluoroacetimidoyl chlorides and isocyanides in dry CH2Cl2 in 
excellent yields (Scheme 8). 
 
Scheme 8 
Masanobu et al.27 have reported the synthesis of N-alkynylpyridinium salts and revealed 
their highly electrophilic nature by means of spectroscopic and electrochemical 
measurements, and demonstrated their further facile conversion into various N-
alkenylpyridiniums via Michael addition and 1,3-dipolar cycloaddition. Further, including 
quinolizinium and azaquinolizinium units were synthesized through intramolecular 
cyclization reactions, which showed a variety of optical and electrochemical properties 
(Scheme 9).   
 
Scheme 9 
Li et al.28 recently developed the synthesis of Isoquinolinium Salts via C-H Activation 
of Imines. Rhodium(III)- catalyzed, redox-neutral coupling reaction between in situ generated 
imines with α diazo ketoesters provided a new method for isoquinolinium synthesis (Scheme 
10). 
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Scheme 10 
 
 
 
2.2.2. Multicomponent reactions (MCRs) 
Multicomponent reactions (MCRs) provide diverse and highly functionalized 
molecules via the formation of multiple bonds29 in a one-pot operation, without isolating the 
intermediates or changing the reaction conditions. It involves the use of three or more 
different starting materials to get a complex product which has incorporated in it most, if not 
all, of the starting materials. MCRs are very useful for diversity oriented synthesis of 
collection of compounds, and also allow a dramatic increase in structurally complexity by 
involving three or more diversity inputs with high degree of atom economy. Hence the very 
large chemical space which is amenable is a major characteristic of MCRs.30 Additionally the 
scaffold diversity of MCR can be greatly enhanced by the introduction of orthogonal 
functional groups into the primary MCR product and further reacting them in subsequent 
transformations, e.g. ring forming reactions (Figure 2).  These features have been routinely 
used in combinatorial and medicinal chemistry for drug discovery processes. 
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Figure 2. Scaffold diversity in MCRs. 
 
 
Among MCRs, IMCRs31 (e.g. Ugi and Passerini reactions) have occupied an 
outstanding position which could be traced to the wide applications in the production of 
diverse and complex small molecule libraries.  
 
 
 
2.2.3. Isocyanides in [4+1] cycloadditon reactions 
 
Figure 3. Synthesis  of  diverse  heterocycles  through isocyanide based formal  [4+1] 
cycloadditions. 
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Owing to the importance of [4+1] cycloadditon and unique reactivity of isocyanides 
several formal [4+1] cycloaddition reactions employing isocyanides as C1 synthon have 
received extreme focus. The formal [4+1] cycloaddition of isocyanide with diverse dienes 
can offer concise construction of five-membered nitrogen heterocyclic compounds such as 
furans, oxazoles, pyrroles, imidazoles, pyrazoles etc., which are highly privileged in nature as 
depicted in Figure 3. 
 
2.2.4 Groebke-Blackburn-Bienayme (GBB) Reaction        
In recent decades, Groebke-Blackburn-Bienayme reaction (GBB)32 a variant of Ugi 
reaction has emerged as an important tool for diversity oriented synthesis of fused 
imidazopyridine derivatives (Figure 4) for their applications in chemistry and biology. 
GBB reaction involves formation of Schiff base by reaction of aminoazine with 
aldehyde. Next the Schiff’s base which holds both the electrophile and nucleophile is 
involved in [4+1] cycloaddition with isocyanide to give bicyclic adduct followed by 
rearomatisation via 1,3-H shift leading to imidazopyridines Scheme 11.32 
 
Scheme 11. Groebke’s, Blackburn’s and Bienaymѐ’s reactions. 
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Figure 4. Different catalysts employed for Groebke–Blackburn–Bienayme reaction to 
generate fused imidazole derivatives. 
 
 
2.2.5 Sustainable Methods: Solvent-Free and Catalyst-Free Reactions 
 Sustainability has become one of the important scientific challenges 
nowadays, due to environmental, health and societal concerns. Due to this, there is a need for 
developing facile, efficient, and non-polluting synthetic procedures to reduce the use of 
organic solvents and toxic reagents. One such approach, which involves green and 
sustainable chemistry,37 drives towards pollution prevention and environmental protection, 
and is now gaining importance. Which mainly involves designing chemical products and 
processes that reduce or eliminate the use of hazardous substances, volatile organic 
compounds, generation of waste materials, by-product formation and unnecessary 
derivatization (like blocking, protecting/deprotecting) etc. 
One of the strategies widely implemented is the development of alternative 
sustainable routes involves catalyst-free and solvent-free reactions (CFR & SFR)38 which 
have gained importance recently. These approaches have several advantages over the 
conventional organic synthetic methods, like (a) reduced pollutant production, (b) reduced 
use or elimination of toxic and hazardous chemicals, (c) operational simplicity, (d) decreasing 
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the reaction time (under SFR), (e) formation of pure products which avoids tedious 
purifications, (f) high yields, (g) reduced cost and many more. Due to the various advantages 
of solvent-free and catalyst-free reactions, from the past decades several groups for the 
synthesis of heterocyclic molecules have made tremendous efforts. 
2.3. Results and Discussion 
 Among IQ derivatives, fused IQ salts are naturally occurring alkaloids and promising 
lead structures in drug discovery. The iminium moiety in these derivatives was found to be 
essential for significant biological activities.8 Though several reports have been documented 
for the synthesis of these derivatives, most of the methods involve starting material with 
preformed IQ skeleton, expensive metal catalysts, multiple steps, lack of diversity, scalability, 
and tedious routes to access starting material.  
Recently, Shen et al. have developed an efficient approach to 
pyridimidazoisoquinolinium compounds via Yb(OTf)3 /AgOTf catalyzed one-pot synthesis 
(Scheme 5).23 However, it involves use of expensive two metal catalysts, inaccessible starting 
material, lack of generality and lengthy synthetic steps. Though there is a convenient 
approach reported for the synthesis of imidazoisoquinolinium salts, it involves preconstructed 
isoquinoline substrate rather than constructing the same.25, 26   
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Scheme 12. Various approaches to imidazopyridine based drug-like molecules via GBB reaction 
 
The versatility of 2-(2-bromoethyl)benzaldehyde (45) as a promising bifunctional 
reactant in various organic transformations has been well documented, especially leading to 
tetrahydroisoquinoline (THIQ) motifs based natural products and their analogues.33 However, 
utilization of 45 in the synthesis of fused dihydroisoquinolinium salts is not explored to date. 
Very recently, in our lab, we have documented some interesting cascade strategies employing 
45 for the synthesis of skeletally diverse THIQ skeletons (Figure 5).33a-c Moreover, we have 
also reported step-economic and sustainable methods for the synthesis of imidazopyridines 
via GBB reaction.34 
Groebke-Blackburn-Bienayme (GBB) reaction is an elegant example involving [4+1] 
cycloaddition as a key step between activated imine i.e. 1,3-diazadiene (1,3-DD) and 
isocyanide resulting in drug-like imidazopyridine heterocyclic entities which are further 
cyclized by post-GBB modifications (Scheme 12). However, most of the methods were 
realized by either use of stoichiometric or catalytic amount of Bronsted acids or bases, Lewis 
acids and metal catalysts for the generation of 1,3-DD and its activation. 
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Figure 5. Various approaches to THIQ motifs starting from bromoethylbenzalaldehyde 
 
Encouraged by our recent reports33a-c on employing 45 in various organic cascade 
transformations, we envisioned that the bifunctional reactivity of 45 could be tapped further 
(Scheme 12b). In this scenario, we conceptualized that 45 on reaction with 2-aminopyridine 
12 would result in cyclic iminium via pre-GBB modification (imine formation and 
alkylation), which can be employed in GBB reaction as activated 1,3-DD under 
metal/catalyst-free conditions.  Herein, we disclose the cyclic iminium induced GBB double 
annulation cascade reaction leading to pyridimidazo-DHIQ salts for the first time. 
Table 1. Double annulation cascade to pyridoimidazo-DHIQ salt 4aaaa,b 
 
entry Solvent temp (°C) time (h) yield (%) 
1 MeOH rt 10 10 
2 MeOH 50 20 20 
3 MeOH 70 22 54 
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4 MeOH 90 20 64 
5 EtOH 100 20 67 
6 H2O 100 20 0 
7 DCE 100 23 40 
8 DCM 50 14 32 
9 CH3CN 90 21 43 
10 THF 90 14 35 
11 1,4 dioxane 110 10 55 
12 No solvent rt 10 trace 
13 No solvent 50 20 40 
14 No solvent 60 2 66 
15 No solvent 80 10 min  91 
16 No solvent 90 10 min 70 
17 No solvent 100 10 min 66 
a Reaction conditions: 45 (0.23 mmol), 12 (0.23 mmol) and 53 (0.23 mmol). b Yield of 
isolated product after column chromatography. 
To test the above hypothesis, a preliminary reaction of equimolar mixture of 2-(2-
bromoethyl) benzaldehyde 45, 2-aminopyridine 12 and cyclohexylisocyanide 53 was 
performed at ambient temperature (35 °C) in methanol for 10h, which afforded the desired 
product 54a, albeit in low yield (Table 1, entry 1). Encouraged by this result, and to further 
explore, we increased the temperatures which resulted in improvement of yields up to 64% 
(Table 1, entries 2-4). Moreover, in protic and aprotic polar solvents, even after continuing 
the reaction for long hours the starting materials were not completely consumed (Table 1, 
entries 5-11). From the perspective of twelve principles of green chemistry, solvent-free 
reactions have seen tremendous growth both in academia and industry.35 Our continued 
interests in development of sustainable methods for synthesis of diverse heterocyclic 
frameworks prompted us to perform the reaction under solvent-free conditions. Not 
surprisingly, higher temperatures resulted in improved yields of the products with drastic 
reduction in time (Table 1, entries 13-15). However, beyond 80 °C we have seen drop in the 
yields (Table 1, entries 16 and 17), which could be due to decomposition of reaction mixture. 
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Scheme 13. Synthesis of pyridoimidazo-DHIQ scaffoldsa,b 
 
a Reactions were performed with 45 (0.23 mmol), 12 (0.23 mmol) and 28 (0.23 mmol) at 80 
oC. b Yield of isolated product after column chromatography. c  
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With the reaction at 80 °C as optimized condition (Table 1, entry 15) for double 
annulation cascade (DAC) in hand we planned to evaluate the scope of our strategy. In this 
direction, we extended it to various aminoazines 12 and isocyanides 28, keeping the aldehyde 
45 component constant to obtain corresponding pyridoimidazoisoquinolinium derivatives 
(Scheme 13, 54a-54k) in good to excellent yields. The structure of 54b was further confirmed 
by single crystal X-ray crystallography. The aminoazine bearing electron withdrawing group 
(EWG), for example chloro substituent gave 54g in moderate yield (64%) compared to other 
aminoazines. We next investigated employing a variety of 2-(2-bromoethyl)benzaldehydes 45 
and aminoazines 12 with EWG and electron donating groups (EDG), which did not show any 
significant difference in the outcome of the reaction. 
Scheme 14. Synthesis of skeletally diverse DHIQ scaffolds a,b  
 
 
a Reactions were performed with 45 (0.23 mmol), 12 (0.23 mmol) and 28 (0.23 mmol) at 80 
oC.  b Yield of isolated product after column chromatography.  
 
Gratifyingly, even when both aminoazines and aldehydes were employed with EWG, it 
resulted in good yield of the product (54s, Scheme 13). Our pursuit for diversity oriented 
synthesis (DOS) impelled us to examine diversity of our present strategy. Accordingly, we 
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probed with structurally and skeletally different aminoazines, which to our delight provided 
interesting and diverse tetra- and pentacyclic IQ scaffolds (Scheme 14). When we have used 
other heterocyclic aminozines we have not observed any detrimental effect on reaction 
outcome. 
After having successfully developed one-pot double annulation cascade (DAC) strategy for 
the synthesis of diverse pyridoimidazo-DHIQ scaffolds via GBB reaction, we envisaged to 
examine the scalability of the process. Consequently, we have performed the reaction on 2-
gram scale and isolated the product 54a as white solid in very good yield (86%) by direct 
filtration without the need for any tedious column purification (Scheme 15). As synthesized 
DHIQ compounds contain some privileged heterocyclic motifs present in drug molecules, the 
scalability of our method should prove industrially applicable.    
 
Scheme 15. Scalability of present DAC protocol 
 
 
Based on our reports33a-c and other literatures,32 we have proposed a plausible 
mechanism for the formation of pyridoimidazo-DHIQ salt 54a in Scheme 16. Initially, the 
reaction of 2-(2-bromoethyl)benzaldehyde 45 and 2-aminopyridine 12 will afford highly 
reactive cyclic iminium I, which on [4+1] cycloaddition with cyclohexylisocyanide 53 will 
lead to pyridoimidazo-DHIQ bromide 54a.    
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Scheme 16. Plausible reaction mechanism for 54a 
 
 
2.4 Conclusion 
In summary, we have developed a mild, efficient and metal-free protocol for the 
synthesis of fused IQ derivatives under solvent-free conditions. We have demonstrated an 
unprecedented cyclic iminium induced GBB leading to construction of two privileged 
heterocyclic rings in one-pot. This double annulation cascade provided pyridoimidazo-
DHIQs in excellent yields by easy isolation without tedious workup. In addition, readily 
accessible starting material, remarkably short reaction time, simplicity in operation, scope of 
skeletal diversity, H2O as sole byproduct and scalability makes this approach greener, cost 
effective, and better alternative to existing ones. On the other hand, the scalability of the 
method should prove appealing for industrial applications. Further studies on biological 
activity of these scaffolds are currently under way in our laboratory.   
 
2.5 Experimental section 
 
General Information 
IR spectra were recorded on the Bruker Tensor 37(FTIR) spectrophotometer. 1H 
NMR spectra were recorded on Bruker Avance 400 (400 MHz) spectrometer at 295K in 
CDCl3; chemical shifts value (δ ppm) and coupling constants (Hz) are reported in standard 
fashion with reference to either tetramethylsilane (TMS) (δH = 0.00 ppm) or CHCl3 (δH = 
7.26ppm). 13C NMR spectra were recorded on Bruker Avance 400 (100 MHz) spectrometer 
at rt in CDCl3; chemical shifts (δ ppm) are reported relative to CHCl3 [(δC = 77.00ppm) 
central line of triplet].  In the 13C NMR, the nature of carbons (C, CH, CH2, and CH3) was 
determined by recording the DEPT- 135 spectra.  In 1H NMR, the following abbreviations 
were used throughout: s = singlet, d = doublet, t = triplet, q = quartet, qui = quintet, m = 
multiplet and br s. = broad singlet.  The assignment of the signals was confirmed by 1H, 13C 
and DEPT spectra.  High-resolution mass spectra (HR-MS) were recorded using Agilent 
6538 UHD Q-TOF using multimode source in +APCI method.  Reactions were monitored by 
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TLC on silica gel (254 mesh) using a combination of petroleum ether and ethyl acetate as 
eluents.   
 
 
 
General procedure 1: Preparation of isochromans 
       A mixture of the substituted phenylethyl alcohol (i) (4.97 mmol), chloromethylmethyl 
ether (7.046 mmol) and N, N-diisopropylethylamine (9.95 mmol) in dry dichloromethane (15 
mL) was stirred under nitrogen atmosphere for 2.5 hours at rt. The reaction mixture was then 
washed with water, dried (Na2SO4) and the solvent was removed in vacuum.  The crude 
MOM acetal (ii) was dissolved in dried acetonitrile and added to cooled (0 oC) solution of 
trimethylsilyl trifluoromethanesulfonate (TMSOTf) (4.97 mmol).  The reaction was carried 
out under nitrogen atmosphere for 3h. Then the mixture was quenched by the addition of l M 
NaHCO3.  The organic phase was washed with brine, dried with anhydrous sodium sulphate 
and evaporated under reduced pressure. Purification by column chromatography afforded 
corresponding substituted isochromans. 
General procedure 2: Preparation of 2-(2-bromoethyl) benzaldehydes 
To a solution of the substituted isochroman iii (7.46 mmol) derivatives in acetonitrile (15 
mL), CuBr2 (8.95 mmol) was added under nitrogen atmosphere. The solution was refluxed 
for about 2h and then cooled to room temperature.  The reaction mixture was added water, 
extracted with ethyl acetate.  The combined organic extracts were washed with brine and 
dried with anhydrous Na2SO4, filtered and concentrated and then purified by silica gel 
column chromatography to afford the products (1a-1c) in 68-74% yield. 
General procedure 3: Synthesis of pyridoimidazo-DHIQ salts 
2-(2-Bromoethyl) benzaldehyde (1, 0.23 mmol) and 2-aminoazine (2, 0.23 mmol) were taken 
in a 5 mL round bottom flask. Then isocyanide 3 (0.23 mmol) was added in succession to the 
reaction mixture and the reaction was stirred at 80 oC for 10-20 min.  After completion of the 
reaction (monitored by TLC in 5% MeOH/DCM, 0.4 Rf), the crude reaction mixture was 
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purified by filtration through a short pad of silica gel (100-200 mesh) column using DCM and 
MeOH as eluents to yield the desired products (4aaa-4akc) in 61-93% yields. 
 
General procedure 4: Large scale synthesis of pyridoimidazodihydroisoquinolinium 
salt: 
2-(2-Bromoethyl) benzaldehyde (45, 2 gm, 9.3 mmol) and 2-aminopyridine (12, 0.87 
gm, 9.3 mmol) were taken in a 25 mL round bottom flask. Then cyclohexylisocyanide (53, 
1.01 gm, 9.3 mmol) was added in succession to the reaction mixture and the reaction was 
stirred at 80 oC for 15 min.  After completion of the reaction (monitored by TLC in 5% 
MeOH/DCM, 0.4 Rf), the crude reaction mixture was washed with 5% ethylacetate in hexane 
to yield the desired product 4aaa (3.2 gm, 86%). 
Spectral Data of all Compounds 
13-(Cyclohexylamino)-5,6 dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-ium 
bromide (54a)   
Physical state   : White solid 
Yield   : 91% 
Mp   : 235-238 ˚C 
IR (MIR-ATR, 4000-600cm-1): νmax = 3411, 3174, 3017, 2927, 2853, 1646, 1615, 1527, 1450, 
1417, 1266, 1224, 1156, 1082, 891, 728; 
1H NMR (CDCl3, 400 MHz): δ ppm = 9.4 (d, J = 6.8 Hz, 1H), 8.35−8.28 (m, 2H), 7.79−7.75 
(m, 1H), 7.37−7.25 (m, 4H), 5.84 (d, J = 6.8 Hz, 1H), 4.65 (t, J = 6.6 Hz, 2H), 3.28 (t, J = 6.6 
Hz, 2H), 3.02−2.95 (m, 1H), 1.87 (d, J = 10.3 Hz, 2H), 1.71−1.52 (m, 5H), 1.19−1.10 (m, 
3H); 
13C NMR (CDCl3, 100 MHz): δ ppm = 134.9, 132.8, 132.4, 130.1, 128.7, 127.9, 127.2, 126.9, 
125.8, 123.3, 122.5, 116.3, 111.0, 58.0, 42.2, 33.9, 28.0, 25.3, 25.1. 
HR-MS (ESI+) m/z calculated for [C21H24N3]
+ = 318.1965; found: 318.1968. 
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13-(Tert-butylamino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-iumbromide 
(54b):  
Physical state   : Pale Yellow solid 
Yield                : 86% 
Mp   : 195-196 ˚C 
IR (MIR-ATR, 4000-600cm-1): νmax = 3192, 3040, 2967, 1647, 1528, 1472, 1365, 1265, 1202, 
1157, 1029, 899, 729, 699, 618. 
1H NMR (CDCl3, 400 MHz): δ ppm = 9.4 (d, J = 6.8 Hz, 1H), 8.62–8.60 (m, 1H), 8.22 (d, J 
= 9.3 Hz, 1H), 7.73 (t, J = 7.8 Hz, 1H), 7.39–7.31 (m, 3H), 7.26–7.24 (m, 1H), 5.61 (s, 1H), 
4.58 (br. s, 2H), 3.28 ( t, J = 5.9 Hz, 2H), 1.25 (s, 9H). 
13C NMR (CDCl3, 100 MHz): δ ppm = 135.4, 133.1, 132.7, 130.5, 128.5, 127.8, 127.7, 127.0, 
125.5, 123.7, 116.1, 110.5, 57.9, 42.4, 30.5, 28. 
HR-MS (ESI+) m/z calculated for [C19H22N3]
+ = 292.1808; found: 292.1812. 
Single crystal X-ray structure data of compound 54b (CCDC 1478558): Thermal 
ellipsoids are drawn at 50% probability level. 
 
 
Identification code exp_4568 
Empirical formula C9.5H11N1.5Br0.5 
Formula weight 372.31 
Temperature/K 300 
Crystal system Triclinic 
Space group P-1 
a/Å 9.8675(5) 
b/Å 10.2949(5) 
c/Å 11.0351(6) 
α/° 117.594(5) 
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β/° 105.751(5) 
γ/° 97.854(4) 
Volume/Å3 909.81(11) 
Z 2 
ρcalcg/cm3 1.3589 
μ/mm-1 3.087 
F(000) 383.5 
Crystal size/mm3 0.6 × 0.4 × 0.2 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 9.74 to 141.4 
Index ranges 
-8 ≤ h ≤ 12, -12 ≤ k ≤ 12, -13 
≤ l ≤ 10 
Reflections collected 7192 
Independent reflections 
3402 [Rint = 0.0439, Rsigma = 
0.0396] 
Data/restraints/parameters 3402/0/214 
Goodness-of-fit on F2 1.050 
Final R indexes [I>=2σ (I)] R1 = 0.0354, wR2 = 0.0904 
Final R indexes [all data] R1 = 0.0396, wR2 = 0.0939 
Largest diff. peak/hole / e Å-3 0.61/-0.65 
 
 
13-(Cyclohexylamino)-8-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-
ium bromide (54c):  
Physical state   : Brown semi solid 
Yield                : 79% 
IR (MIR-ATR, 4000−600 cm-1): νmax = 3744, 3669, 3395, 3182,3007, 2925, 2850, 2350, 
2155, 1983, 1726, 1633, 1570, 1511, 1489, 1451, 1421, 1368, 1302, 1260, 1210, 1090, 1040, 
949, 889, 802, 763, 731, 668, 605, 558. 
1H NMR (400 MHz, CDCl3): δ ppm = 9.35 (d, J = 6.8 Hz, 1H), 8.40−8.38 (m, 1H), 7.5 (d, J 
= 6.8 Hz, 1H), 7.42−7.35 (m, 3H), 7.25−7.23 (m, 1H), 5.86 (br. s, 1H), 4.84 (t, J = 6.6 Hz, 
2H), 3.33 (t, J = 6.6 Hz, 2H), 3.01 (t, J = 10.8 Hz, 1H), 2.92 (s, 3H), 1.87 (d, J = 10.3 Hz, 
2H), 1.73−1.62 (m, 4H), 1.56 (dd, Ja = 15.2 and Jb = 11.2 Hz, 2H), 1.26−1.16 (m, 2H).  
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13C NMR (100 MHz, CDCl3): δ ppm = 134.6, 134.5, 132.1, 129.9, 128.2, 127.9, 127.4, 126.0, 
125.5, 123.6, 123.0, 121.7, 116.2, 57.6, 44.2, 33.8, 28.7, 25.3, 25.1, 20.1. 
 HR-MS (ESI+): m/z calculated for [C22H26N3]
+ = 332.2121; found: 332.2131. 
 
13-(Cyclohexylamino)-9-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-
ium bromide (54d): 
Physical state : White solid 
Yield  : 93% 
Mp  : 235-238 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3424, 3175, 3007, 2926, 2853, 2453, 1967, 1651, 
1532, 1457, 1312, 1263, 1233, 1152, 1083, 889, 604, 540. 
1H NMR (400 MHz, CDCl3): δ ppm = 9.22–9.18 (m, 1H), 8.27–8.25 (m, 1H), 8.06–8.03 (m, 
1H), 7.31–7.30 (m, 3H), 7.06 (d, J = 6.8 Hz, 1H), 5.65–5.61 (m, 1H), 4.55 (t, J = 6.4 Hz, 2H), 
3.26–3.23 (m, 2H), 2.97–2.94 (m, 1H), 2.5 (s, 3H), 2.11 (br. s, 1H), 1.84 (d, J = 7.8 Hz, 3H),  
1.69 (br. s, 2H), 1.58–1.53 (m, 2H), 1.23–1.14 (m, 3H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 145.8, 135.3, 132.3, 129.9, 128.7, 127.9, 126.7, 
126.1, 125.7, 123.5, 122.0, 118.8, 109.3, 57.9, 41.9, 33.9, 28.0, 25.3, 25.1,21.8. 
HR-MS (ESI+): m/z calculated for [C22H26N3]
+ = 332.2121; found: 332.2127. 
 
13-(Cyclohexylamino)-11-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-
ium bromide (54e):  
Physical state : White solid 
Yield  : 83% 
Mp  : 295-297 ˚C 
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IR (MIR-ATR, 4000–600 cm-1): νmax = 3744, 3733, 3395, 3196, 3085, 3007, 2923, 2851, 
2373, 2350, 2320, 2129, 1992, 1947, 1731, 1632, 1512, 1464, 1453, 1420, 1303, 1260, 1171, 
1091, 1040, 889, 803, 763, 744, 668, 605, 576, 559. 
 1H NMR (DMSO D6, 400 MHz): δ ppm = 8.71 (d, J = 6.8 Hz, 1H), 8.34 (d, J = 6.8 Hz, 1H), 
7.71 (d, J = 6.8 Hz, 1H), 7.45–7.41 (m, 4H), 5.56 (d, 1H), 4.87 (t, J = 6.4 Hz, 2H), 3.31–3.27 
(m, 2H), 2.95 (s, 1H), 2.9 (s, 3H), 1.85 (d, J = 11.7 Hz, 2H), 1.7 (br. s, 2H), 1.56 (br. s, 1H), 
1.37 (d, J = 10.3 Hz, 2H), 1.15 (br. s, 3H). 
13C NMR (100 MHz, DMSO D6): δ ppm = 134.8, 134.0, 129.6, 128.2, 127.3, 125.9, 125.2, 
123.3, 122.8, 122.5, 116.2,56.5, 33.3, 27.8, 25.0,24.5,19.0. 
 HR-MS (ESI+): m/z calculated for [C22H26N3]
+ = 332.2121; found: 332.2120. 
 
8-(Benzyloxy)-13-(cyclohexylamino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1a]isoquinolin-
7-ium bromide (54f):  
Physical state : Brown solid 
Yield  : 71% 
Mp  : 157-158 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3744, 3733, 3395, 3196, 3085, 3007, 2923, 2851, 
2373, 2350, 2320, 2129, 1992, 1947, 1731, 1632, 1512, 1464, 1453, 1420, 1303, 1260, 1171, 
1091, 1040, 889, 803, 763, 744, 668, 605, 576, 559. 
 1H NMR (400 MHz, CDCl3): δ ppm = 9.06 (d, J = 6.4 Hz, 1H), 8.4 (d, J = 6.8 Hz, 1H), 7.5-
7.49 (m, 2H), 7.44-7.41 (m, 4H), 7.39-7.35 (m, 2H), 7.33-7.31 (m, 2H), 6.02 (d, J = 6.4 Hz, 
1H), 5.4 (s, 2H), 4.75 (t, J = 6.4 Hz, 2H), 3.2 (t, J = 6.4 Hz, 2H), 3.01-2.98 (m, 1H), 1.87 (d, J 
= 12.2 Hz, 2H), 1.7-1.5 (m, 5H), 1.4-1.09 (m, 3H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 144.5, 134.2, 132.1, 129.9, 129.0, 128.2, 128.1, 
128.0, 127.9, 126.1, 123.5, 123.0, 119.8, 116.6,112.4, 72.6, 57.7, 44.1, 33.8, 28.4, 25.3, 25.1. 
  HR-MS (ESI+): m/z calculated for [C28H30N3O]
+ = 424.2383; found: 424.2398.  
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10-Chloro-13-(cyclohexylamino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-
ium bromide (54g):  
Physical state : Pale yellow solid 
Yield  : 63% 
Mp  : 158-160 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3745, 3396, 3174, 2923, 2852, 1955, 1731, 1646, 
1612, 1522, 1467, 1451, 1305, 1264, 1226, 1050, 888, 808, 767, 731. 
1H NMR (DMSO D6, 400 MHz): δ ppm = 9.13 (s, 1H), 8.35–8.27 (m, 2H), 8.09 (dd, Ja = 9.3 
and Jb = 1.5 Hz, 1H), 7.52–7.46 (m, 3H), 5.68 (d, J = 6.8 Hz, 1H), 4.6 (t, J = 6.6 Hz, 2H), 3.3 
(t, J = 6.4 Hz, 2H), 2.98–2.95 (m, 1H), 1.87 (d, J = 11.7, 2H), 1.67 (br. s, 2 H ), 1.53 (br. s, 1 
H), 1.37 (d, J = 9.8 Hz, 2H), 1.23–1.13 (m, 3H). 
 13C NMR (DMSO D6, 100 MHz): δ ppm = 134.0, 133.4, 132.9, 129.9, 128.8, 127.5, 126.5, 
125.2, 123.6, 123.2, 122.9, 112.2, 79.2, 56.8, 41.3, 33.1, 26.9, 25.1, 24.6. 
HR-MS (ESI+): m/z calculated for [C21H23ClN3]
+ = 352.1575; found: 352.1590. 
 
13-((2-Ethoxy-2-oxoethyl)amino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-
ium bromide (54h):  
Physical state : Brown semisolid  
Yield  : 68% 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3774, 3654, 3179, 3037, 2981, 2032, 1975, 1739, 
1649, 1622, 1527, 1449, 1408, 1265, 1197, 1155, 1110, 1022, 862, 727, 697, 600. 
 1H NMR (400 MHz, CDCl3 ): δ ppm = 9.5 (d, 1H), 8.20–8.18 (m, 1H), 8.1 (d, J = 8.8 Hz, 
1H), 7.28–7.74 (m, 1H), 7.41–7.38 (m, 2H), 7.37–7.33 (m, 1H), 7.26–7.24 (m, 1H), 6.84 (t, J 
= 6.24 Hz, 1H), 4.58 (t, J = 6.6 Hz, 2H), 4.02–3.96 (m, 4H), 3.28 (t, J = 6.4 Hz, 2H), 1.12 (t, 
J = 7.1 Hz, 3H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 171.5, 134.8, 132.9, 132.3, 130.2, 128.8, 128.4, 
127.7, 125.5, 123.0, 121.0, 115.8, 109.9, 61.1, 47.5, 42.1, 28.0, 14.0. 
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 HR-MS (ESI+): m/z calculated for [C19H20N3O2]
+ = 322.1550; found: 322.1554. 
 
13-((2-Ethoxy-2-oxoethyl)amino)-9-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54i): 
Physical state : Brown semisolid 
Yield  : 73% 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3412, 3189, 2981, 2066, 2015, 1738, 1654, 1629, 
1532, 1462, 1406, 1372, 1262, 1199, 1107, 1025, 859, 769, 729, 697, 608. 
1H NMR (400 MHz, CDCl3): δ ppm = 9.4 (d, J = 6.8 Hz, 1H), 8.17-8.15 (m, 1H), 7.9 (s, 1H), 
7.40-7.34 (m, 3H), 7.07 (dd, J = 7.3 Hz, 1H), 6.78 (t, J = 6.4 Hz, 1H), 4.52 (t, J = 6.6 Hz, 
2H), 4.01-3.96 (m, 4H), 3.26 (t, J = 6.4 Hz, 2H), 2.53 (s, 3H), 1.13 (t, J = 7.1 Hz, 3H). 
13C NMR (100 MHz, CDCl3): δ ppm = 171.6, 145.9, 135.1, 132.2, 129.9, 128.8, 128.4, 128.1, 
128.3, 127.6, 127.2, 125.4, 123.2, 120.4, 118.2, 108.5, 61.1, 47.5, 41.9, 28.0, 21.9, 14.0. 
HR-MS (ESI+): m/z calculated for [C20H22N3O2]
+ = 336.1707; found: 326.1712. 
 
13-((2-Ethoxy-2-oxoethyl)amino)-11-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54j):  
Physical state : Brown semisolid 
Yield  : 79%  
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3745, 3180, 3035, 2957, 2318, 1986, 1738, 1649, 
1530, 1472, 1456, 1302, 1265, 1113, 1022, 948, 864, 768, 727, 697, 663, 602, 574. 
1H NMR (400 MHz, CDCl3 ): δ ppm = 8.29  (dd, J = 5.1, 3.7 Hz, 1H), 8.02 (d, J = 9.3 Hz, 
1H), 7.7 (dd, Ja = 9.3 and Jb = 7.3 Hz, 1H), 7.39-7.31 (m, 3H), 6.99 (d, J = 6.8 Hz, 1H), 6.29 
(t, J = 4.4 Hz, 1H), 4.53 (t, J = 6.4 Hz, 2H), 4.03-3.96 (m, 4H),  3.38 (s, 3H), 3.27 (t, J = 6.6 
Hz, 2H), 1.13 (t, J = 7.1 Hz, 3H). 
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 13C NMR (100 MHz, CDCl3): δ ppm = 171.3, 142.4, 136.8, 133.3, 132.9, 130.4, 128.8, 
128.6, 128.4, 126.3, 124.1, 122.7, 118.6, 108.2, 60.9, 47.9, 41.9, 28.1, 21.6, 14.0. 
 HR-MS (ESI+) m/z calculated for [C20H22N3O2]
+ = 336.1707; found: 336.1713. 
13-(Benzylamino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-iumbromide 
(54k):  
Physical state : White solid 
Yield  : 81% 
Mp   : 232-235 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3745, 3397, 3195, 2978, 2943, 2690, 1691, 1649, 
1527, 1469, 1453, 1392, 1314, 1227, 1159, 1068, 1026, 755, 734, 702, 632. 
1H NMR (400 MHz, CDCl3): δ = 9.03 (d, J = 6.8 Hz, 1H), 8.25-8.24 (m, 1H), 8.17 (d, J = 9.3 
Hz, 1H), 7.66 (ddd, Ja = 9, Jb = 7.1 and Jc = 1 Hz, 1H), 7.38-7.36 (m, 3H), 7.18 (dd, Ja = 6.6 
and Jb = 2.7 Hz, 2H), 7.08-7.05 (m, 4H), 6.74 (t, J = 5.9 Hz, 1H), 4.58 (t, J = 6.6 Hz, 2H), 
4.32 (d, J = 5.4 Hz, 2H), 3.21 (t, J = 6.4 Hz, 2H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 138.6, 134.7, 132.7, 132.3, 130.2, 128.6, 128.4, 
128.1, 127.6, 127.5, 126.6, 126.1, 123.0, 122.3, 116.0, 110.5, 51.0, 42.1, 28.1. 
 HR-MS (ESI+): m/z calculated for [C22H20N3]
 += 326.1652; found: 326.1663. 
 
2-Bromo-13-(cyclohexylamino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-a]isoquinolin-7-
ium bromide (54l):  
Physical state : Pale yellow solid 
Yield  : 72% 
Mp   : 275-278 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3779, 3426, 3192, 3025, 2927, 2853, 1929, 1648, 
1622, 1526, 1467, 1449, 1342, 1318, 1292, 1258, 1229, 1085, 874, 833, 759, 597. 
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1H NMR (400 MHz, CDCl3): δ ppm = 9.48-9.46 (m, 1H), 8.38-8.37 (m, 1H), 8.24-8.21 (m, 
1H), 7.73-7.69 (m, 1H), 7.46-7.43 (m, 1H), 7.24-7.21 (m, 2H), 6.03 (d, J = 7.3 Hz, 1H), 4.64 
(t, J = 6.6 Hz, 2H), 3.26 (t, J = 6.4 Hz, 2H), 2.96-2.93 (m, 1H), 1.87 (d, J = 12.2 Hz, 2H), 1.7-
1.5 (m, 5H), 1.4-1.09 (m, 3H). 
13C NMR (100 MHz, CDCl3): δ = 135.1, 133.2, 132.8, 131.1, 130.3, 128.3, 128.0, 127.2, 
125.1, 121.6, 120.7, 116.5, 111.0, 58.5, 42.2, 34.1, 27.5, 25.24, 25.2. 
 HR-MS (ESI+): m/z calculated for [C21H23BrN3]
+ = 396.1070; found: 396.1067. 
 
2-Bromo-13-(cyclohexylamino)-9-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1 
a]isoquinolin-7-ium bromide (54m):  
Physical state : White solid 
Yield  : 78% 
Mp   : 180-183 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3779, 3638, 3407, 3317, 3197, 3041, 2927, 2853, 
1975, 1652, 1622, 1559, 1531, 1446, 1372, 1313, 1259, 1185, 1084, 1040, 890, 808, 730, 
603, 563. 
1H NMR (400 MHz, CDCl3): δ ppm = 9.3 (d, J = 7.3 Hz, 1H), 8.32 (d, J = 2 Hz, 1H), 8.05 (s, 
1H), 7.36 (dd, J = 8.3 Hz, 1H), 7.18 (d, J = 8.3 Hz, 1H), 7.06 (d, J = 6.4 Hz, 1H), 5.94 (d, J = 
6.8 Hz, 1H), 4.55 (t, J = 6.4 Hz, 2H), 3.2 (t, J = 6.4 Hz, 2H), 2.91-2.84 (m, 1H), 2.5 (s, 3H), 
1.83-1.80 (m, 2H), 1.67 (d, J = 10.3 Hz, 2H), 1.60-1.49 (m, 3H), 1.14-1.11 (m, 3H). 
13C NMR (100 MHz, CDCl3): δ = 146.2, 135.4, 132.4, 130.9, 130.3, 128.1, 127.6, 126.5, 
125.2, 121.5, 120.0, 118.9, 109.5, 58.5, 41.8, 34.0, 27.5, 25.2, 25.1, 21.9. 
 HR-MS (ESI+): m/z calculated for [C22H25BrN3]
+ = 410.1226; found: 410.1228. 
 
2-Bromo-9-chloro-13-(cyclohexylamino)-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54n):  
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Physical state : Pale yellow  
Yield  : 68% 
Mp   : 155-157 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3691, 3570, 3406, 3181, 3006, 2927, 2853, 1977, 
1707, 1647, 1616, 1597, 1560, 1522, 1464, 1424, 1369, 1343, 1308, 1257, 1097, 1078, 945, 
890, 840, 816, 731, 665. 
 1H NMR (400 MHz, CDCl3): δ = 9.47 (d, J = 7.3 Hz, 1H), 8.53 (d, J = 9.3 Hz, 1H), 8.32 (d, J 
= 2Hz, 1H), 7.66 (d, J = 8.8 Hz, 1H), 7.48 (dd, J = 7.8 Hz, 1H), 7.24 (d, J = 8.3 Hz, 1H), 5.96 
(d, J = 7.3 Hz, 1H), 4.76 (t, J = 6.4 Hz, 2H), 3.27 (t, J = 6.1 Hz, 2H), 2.96-2.94 (m, 1H), 1.86 
(m, J = 9.3 Hz, 2H), 1.76 (d, J = 12.7 Hz, 2H), 1.60-1.64 (m, 4H), 1.22-1.18 (m, 2H). 
 13C NMR (100 MHz, CDCl3): δ = 133.9, 133.5, 132.4, 133.2, 131.2, 130.3, 128.4, 127.9, 
125.2, 124.7, 124.4, 121.7, 112.4, 58.4, 42.8, 34.1, 27.4, 25.2, 25.1. 
 HR-MS (ESI+): m/z calculated for [C21H22BrClN3]
+ = 430.0680; found: 430.0689. 
 
10-Chloro-13-(cyclohexylamino)-2-methyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54o):  
Physical state : White solid 
Yield  : 76% 
Mp   : 228-230 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3413, 3180, 2926, 2853, 2028, 1647, 1613, 1524, 
1490, 1450, 1344, 1307, 1266, 1228, 1148, 1093, 1049, 947, 890, 817, 730, 699, 602, 558. 
 1H NMR (400 MHz, CDCl3): δ = 9.41 (d, J = 1 Hz, 1H), 8.54 (d, J = 9.8 Hz, 1H), 8.1 (s, 1H), 
7.61 (dd, Ja = 9.5 and Jb = 1.7 Hz, 1H), 7.22-7.18 (m, 2H), 5.9 (d, J = 6.8 Hz, 1H), 4.69 (t, J 
= 6.6 Hz, 2H), 3.23 (t, J = 6.6 Hz, 2H), 3.0-2.97 (m, 1H), 2.4 (s, 3H), 1.88-1.80 (m, 3H), 
1.72-1.58 (m, 4H), 1.28-1.18 (m, 3H). 
 13C NMR (100 MHz, CDCl3): δ = 137.9, 133.3, 133.1, 131.3, 129.4, 128.5, 127.2, 126.3, 
124.9, 124.2, 123.6, 122.7, 112.2, 57.9, 43.1, 34.1, 27.4, 25.2, 25.1, 21.2. 
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 HR-MS (ESI+): m/z calculated for [C22H25ClN3]
+ = 366.1732; found: 366.1738.  
 
13-(Cyclohexylamino)-2,11-dimethyl-5,6-dihydropyrido[2',1':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54p):  
Physical state : Pale yellow solid  
Yield  : 74% 
Mp   : 217-219 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3395, 3195, 3027, 2925, 2852, 1729, 1646, 1532, 
1491, 1449, 1420, 1386, 1264, 1210, 1140, 1110, 868, 820, 781, 727, 696, 592. 
1H NMR (CDCl3, 400 MHz): δ = 8.25 (s, 1H), 8.11(d, J = 8.8 Hz, 1H), 7.63 (dd, J = 8.8 Hz, 
1H), 7.18-7.13 (m, 2H), 6.93 (d, J = 7.3 Hz, 1H), 5.12 (d, J = 2.4 Hz, 1H), 4.51 (t, J = 6.4 Hz, 
2H), 3.26 (s, 3H), 3.18 (t, J = 6.4 Hz, 2H), 2.97-2.91 (m, 1H), 2.02 (br. s, 1H), 1.8 (d, J = 
12.2 Hz, 2H), 1.64-1.52 (m, 3H), 1.3-1.18 (m, 4H), 1.09-1.05 (m, 3H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 141.0, 137.7, 136.9, 133.1, 131.2, 130.0, 128.2, 
127.5, 127.2, 126.2, 123.1, 118.8, 108.9, 58.1, 42.2, 33.3, 29.6, 27.8, 25.6, 24.8, 21.2, 21.2; 
HR-MS (ESI+) m/z calculated for [C23H28N3]
+ = 346.2278; found: 346.2277. 
 
13-((2-Ethoxy-2-oxoethyl)amino)-5,6-dihydropyrimido[2',1':2,3]imidazo[5,1-a]isoquinolin-
7-ium bromide (54q):  
Physical state : White solid 
Yield  : 63% 
Mp  : 186-188 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3185, 3102, 2181, 2123, 1969, 1738, 1641, 1609, 
1536, 1471, 1436, 1376, 1333, 1274, 1207, 1154, 1111, 1030, 760, 736, 637, 568. 
1H NMR (CDCl3, 400 MHz): δ ppm = 10.22 (dd, Ja = 7.1 and Jb = 1.7 Hz, 1H), 8.81 (s, 1H), 
8.21-8.19 (m, 1H), 7.51 (dd, Ja = 6.8 and Jb = 4.4 Hz, 1H), 7.46-7.38 (m, 3H), 7.19 (t, J = 6.6 
Hz, 1H), 4.60-4.57 (m, 2H), 4.0-3.96 (m, 4H), 3.28 (t, J = 6.6 Hz, 2H), 1.12 (t, J = 7.1 Hz, 
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3H).  13C NMR (100 MHz, CDCl3): δ = 171.8, 155.7, 138.0, 137.9, 132.6, 130.7, 128.9, 
128.6, 126.5, 125.9, 122.8, 121.3, 122.8, 61.2, 47.3, 40.6, 27.8, 14.0. 
 HR-MS (ESI+): m/z calculated for [C18H19N4O2]
+ = 323.1503; found: 323.1509. 
 
13-(Cyclohexylamino)-5,6-dihydropyrazino[2',1':2,3]imidazo[5,1-a]isoquinolin-7-ium 
bromide (54r):  
Physical state : Green solid 
Yield  : 68% 
Mp   : 197-199 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3422, 3182, 3040, 2930, 2855, 1584, 1529, 1294, 
1264, 1083, 1027, 892, 768, 728, 698, 593, 570. 
 1H NMR (400 MHz, CDCl3): δ = 9.97 (s, 1H), 9.43 (d, J = 3.9 Hz, 1H), 8.31-8.28 (m, 2H), 
7.42-7.35 (m, 3H), 6.11 (d, J = 7.8 Hz, 1H), 4.93 (t, J = 6.4 Hz, 2H), 3.36 (t, J = 6.4 Hz, 2H), 
3.02-2.98 (m, 1H), 1.85 (d, J = 10.8 Hz, 2H), 1.71-1.51 (m, 5H), 1.19-1.09 (m, 3H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 137.0, 133.9, 133.0, 131.1, 128.9, 128.5, 128.1, 
126.3, 124.2, 122.7, 118.5, 58.1, 43.3, 34.0, 27.7, 25.1; 27.4, 25.2, 25.1, 21.2. 
 HR-MS (ESI+): m/z calculated for [C20H23N4]
 + = 319.1917; found: 319.1933.  
 
13-((2-Ethoxy-2-oxoethyl) amino)-5,6-dihydropyrazino[2',1':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54s):  
Physical state : White solid 
Yield  : 61% 
Mp   : 212-214 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3744, 3733, 3611, 3395, 3162, 2977, 2378, 2322, 
2211, 2154, 2130, 1992, 1735, 1679, 1640, 1587, 1530, 1471, 1394, 1298, 1201, 1114, 1025, 
931, 856, 770, 652, 605, 575. 
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 1H NMR (400 MHz, CDCl3): δ ppm = 9.7 (d, J = 1.5 Hz, 1H), 8.97 (dd, J = 4.6 Hz, 1H), 8.56 
(d, J = 4.4 Hz, 1H), 8.24-8.22 (m, 1H), 7.56-7.53 (m, 3H), 6.51-6.47 (m, 1H), 4.74 (t, J = 6.6 
Hz, 2H), 4.05-3.98 (m, 4H),  3.31 (t, J = 6.8 Hz, 2H), 1.1 (t, J = 7.1 Hz, 3H). 
 13C NMR (100 MHz, CDCl3): δ ppm = 171.1, 137.5, 133.9, 133, 130.6, 128.9, 127.9, 127.5, 
122.8, 122.6, 118.0, 60.7, 47.6, 41.7, 26.7, 13.8. 
 HR-MS (ESI+):m/z calculated for [C18H19N4O2]
 + = 323.1503; found: 323.1512. 
14-(Cyclohexylamino)-11-methoxy-5,6-dihydrobenzo[4',5']thiazolo[2',3':2,3]imidazo[5,1-
a]isoquinolin-7-ium bromide (54t):  
Physical state : White solid 
Yield  : 70% 
Mp   : 292-293 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3745, 3730, 3670, 3611, 3395, 3181, 2926, 2852, 
2370, 2322, 2168, 2128, 1992, 1840, 1786, 1678, 1641, 1535, 1484, 1451, 1301, 1246, 1164, 
1028, 870, 818, 706, 667, 590, 574. 
 1H NMR (DMSO D6, 400 MHz): δ ppm = 8.28-8.22 (m, 2H), 8.01 (d, J = 2.4, 1H), 7.48-7.37 
(m, 4H), 5.67 (d, J = 5.9 Hz, 1H), 4.45 (t, J = 6.4 Hz, 2H), 3.89 (s, 3H), 3.25 (t, J = 6.6 Hz, 
2H), 2.97-2.94 (m, 1H), 1.94 (d, J = 11.7 Hz, 2H), 1.66 (br. s, 2H), 1.53 (m, 1H), 1.33-1.28 
(m, 2H), 1.11 (br. s, 3H). 
 13C NMR (100 MHz, DMSO D6): δ ppm = 157.9, 141.6, 132.1, 130.4, 129.0, 128.8, 127.4, 
125.7, 125.1, 124.3, 124.0, 116.5, 115.4, 109.6, 57.2, 56.0, 43.6, 32.8, 27.2, 25.2, 24.5. 
 HR-MS (ESI+): m/z calculated for [C24H26BrN3OS]
+ = 404.1791; found: 404.1787.   
 
14((2Ethoxy2oxoethyl)amino)11 methoxy5,6 dihydrobenzo[4',5']thiazolo[2',3':2,3]imidazo 
[5,1-a]isoquinolin-7-ium bromide (54u): 
Physical state : White solid 
Yield  : 68% 
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Mp   : 242-244 ˚C 
IR (MIR-ATR, 4000–600 cm-1): ʋmax = 3190, 2976, 2935, 1740, 1604, 1539, 1479, 1464, 
1377, 1300, 1273, 1236, 1200, 1111, 1092, 1045, 1019, 813, 769, 726, 691, 596. 
 1H NMR (DMSO D6, 400 MHz): δ ppm = 8.47 (d, J = 8.8 Hz, 1H), 8.11 (d, J = 7.3 Hz, 1H), 
7.98 (d, J = 2 Hz, 1H), 7.49-7.40 (m, 3H), 7.33 (dd, J = 9, 2.2 Hz, 1H), 6.16 (s, 1H), 4.45 (t, J 
= 6.4 Hz, 2H), 4.04-3.97 (m, 4H), 3.89 (s, 3H), 3.23 (t, J = 6.1 Hz, 2H), 1.06 (t, J = 7.1 Hz, 
3H). 
 13C NMR (100 MHz, DMSO D6): δ ppm = 171.1, 130.7, 130.0, 129.6, 128.7, 125.1, 115.6, 
61.0, 56.0, 14.0. 
HR-MS (ESI+): m/z calculated for [C22H22BrN3O3S]
+ = 408.1376; found: 408.1381. 
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1H NMR (400 MHz) spectrum of compound 54a in CDCl3    
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13C NMR (100 MHz) spectrum of compound 54a in CDCl3 
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1H NMR (400 MHz) spectrum of compound 54b in CDCl3   
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13C NMR (100 MHz) spectrum of compound 54b in CDCl3 
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1H NMR (400 MHz) spectrum of compound 54c in CDCl3 
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13C NMR (100 MHz) spectrum of compound 54c in CDCl3 
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1H NMR (400 MHz) spectrum of compound 54d in CDCl3 
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13C NMR (100 MHz) spectrum of compound 54d in CDCl3 
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1H NMR (400 MHz) spectrum of compound 54e in CDCl3 
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1H NMR (400 MHz) spectrum of compound 54s in DMSO-d6 
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1H NMR (400 MHz) spectrum of compound 54t in CDCl3 
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1H NMR (400 MHz) spectrum of compound 54u in DMSO-d6 
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CHAPTER 3 
An Exocyclic N-Acyliminium ion (NAI) Cyclization: 
Access to Fully Substituted Oxazoles and 
Furocoumarins 
 
3.1 Introduction 
3.1.1. Reactivity of N-Acyliminium ions (NAI’s) 
As an important subfamily of the iminium ion classes, NAIs are more reactive than 
other types of iminium ions because of the electron-withdrawing nature of the carbonyl group 
(Figure 1).  
Among all the cyclization methods in organic synthetic chemistry, NAI based 
cyclization methods have emerged as a powerful versatile approach1 for accessing 
structurally diverse scaffolds of broad biological interest.  
Here the beauty of NAI was, it can able to trap with various nucleophiles such as very 
strong to very weak. Most methods involve trapping the intermediate NAI with heteroatom 
nucleophiles or π-type carbon nucleophiles, including aromatic and heteroaromatic rings, as 
well as double and triple bonds. The viability of the intramolecular cyclization depends on 
both strength and ability to form the NAI and the reactivity of the nucleophiles. 
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Figure 1: Classification of iminium ion chemistry 
3.1.2. Types of N-Acyliminium ions 
Chemists have developed N-acyl iminium ion based biomimetic approaches for the 
synthesis of various alkaloids inspired by nature’s design principles.2 Owing to their 
significant importance, chemists have been paid substantial attention to the development of a 
variety of NAI precursors and structurally related chemo types (Figure 2). 
 
 
Figure 2. Structures of N-acyliminium ion (NAI) and structurally related chemotypes 
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Among them, pyrrolidine based NAI ion precursors3 have obtained a dominant 
position for enabling powerful access to the generation of cyclic NAIs particularly endo-
cyclic (Figure 3) by the treatment of Brønsted acid or Lewis acid, and which are mainly 
limited to intramolecular cyclization reactions.4 However, the synthesis of these NAI 
precursors often required multistep syntheses.3  
 
 
Figure 3. Literature known NAIs and our designed NAI  
The development of a direct route to access NAI precursors and their further 
transformations toward diverse scaffolds in a single pot is a daunting challenge. The reason is 
the formation of NAI ion species prerequisite is a good leaving group at the α-position to the 
nitrogen atom. In order to bring leaving groups at the desired position in substrates involves 
multistep syntheses and which are highly difficult to operate in single pot.  
 
3.2. Background 
3.2.1. Selective Methods for Oxazoles synthesis 
Recently, Jiang et al.5 have developed an efficient approach to butenolides and 
oxazoles via metal-catalyzed [2 + 3] cyclization. In this work a copper-catalyzed [2 + 3] 
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formal cyclization reaction between α-hydroxyl ketones and aryl-acetonitriles has been 
developed. Tertiary α-hydroxy ketones gave 3,4,5,5-tetrasubstituted butenolides as the sole 
products, while secondary α-hydroxy ketones furnished 2,4,5 trisubstituted oxazoles 
selectively (Scheme 1). 
 
Scheme 1 
Taylor et al.6 prepared substituted oxazoles by Ritter reaction. The Lewis acid 
catalyzed Ritter reaction of a-oxo tosylates with nitriles forms the basis of an efficient 
synthesis of oxazoles. The Ritter reaction of a-carbonyl carbocations represents a useful 
strategy for the preparation of trisubstituted oxazoles.  
 
Scheme 2 
Recently, Wu et al.7 have reported an acid-promoted multi component reaction for the 
synthesis of diverse fully substituted oxazole derivatives from simple and readily available 
arylglyoxal monohydrates, nitriles, and various C-nucleophiles has been developed. This 
work demonstrates that a traditional Robinson−Gabriel reaction served as the key advance for 
this transformation. 
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Scheme 3 
In 2015, Zhong et al.8 a Triflic acid-catalyzed chemo selective [3 + 2] cycloaddition 
of donor and acceptor oxiranes and nitriles is described. The reactions involve in situ 
generation of 1,3-dipoles through Lewis acid promoted C−C bond or C−O bond cleavage of 
oxiranes, which are then trapped by dipolarophiles bearing C−X (X = O, C) multiple bonds. 
 
  
Scheme 4 
In 2015 Peddinti et al.9 have developed a hypervalent iodine mediated synthesis of di- 
and tri-substituted isoxazoles via [3+2] cycloaddition of nitrile oxides. 
 
Scheme 5 
In 2012, Hanzawa et al.10 highly substituted oxazoles from ketones and nitriles by the 
use of iodosobenzene with trifluoromethanesulfonic acid or 
bis(trifluoromethanesulfonyl)imide.  
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Scheme 6 
In 2015, Zhao et al.11 developed transition-metal free heterocyclization reaction 
between 1,3-diynes with N,O-bis(trimethylsiyl)acetamide was accomplished in the presence 
of tBuOK and acetonitrile at 120 °C. This method regioselectively gave 2,4,5-trisubstituted 
oxazoles. 
 
Scheme 7 
 
In 2010, Qi et al. 12 developed a new type of one-pot, transition-metal free protocol 
through a TBHP/I2-mediated oxidative cyclization from easily available aryl alkenes and 
benzylic amines for the synthesis of polysubstituted oxazoles.  
 
Scheme 8 
In 2014, Jiang et al.13 developed a novel and effective method has been developed to 
construct highly substituted oxazoles via a palladium-catalyzed dehydration/C-H 
functionalization/C-O bond-forming reaction between amides and ketones.  
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Scheme 9 
In 2016, Wang et al.14 developed a novel three-component cyclization reaction of 2H-
azirines, alkynyl bromides, and molecular oxygen under visible light photoredox catalysis at 
room temperature has been developed, which provides a direct approach to a wide range of 
substituted oxazoles in this method they used acridinium salt (PC-I, 5.0 mol %) as an organic 
photocatalyst at room temperature under visible light irradiation. The radical cycloaddition 
proceeded smoothly to generate oxazoles in moderate to good yields under mild reaction 
conditions. 
 
Scheme 10 
3.2.2. Selective Methods for furocoumarins synthesis 
In 2013, Wang et al.15 have developed 2-alkylamino-3-aryl-4H-furo[3,2-c]chromen-4 
ones via a one-pot, multicomponent reaction from substituted nitrostyrenes, aromatic 
aldehydes, 4-hydroxycoumarin, and ammonium acetate which involves sequential Michael 
addition, aza-nucleophilic addition of imine to the double bond, intermolecular nucleophilic 
addition, and dehydration reactions. 
 
Scheme 11 
In 2015, Feng et al.16 have developed an efficient synthetic method for the synthesis 
of furo[3,2-c]coumarins from readily available 4-oxohydrocoumarins and alkenes. This 
operationally simple method gives a rapid access to the furo[3,2-c]coumarins. 
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Scheme 12 
In 2012 Sameh et al.17 have developed a new method for the synthesis of angular 
furocoumarins were carried out through Williamson reaction of 4‐hydroxycoumarin 
with α‐haloketones followed by cyclization. Photooxygenation of the synthesized 
furocoumarin derivatives was performed and the photoproducts were isolated and 
characterized. 
 
Scheme 13 
 
Sharma et al.18 developed a green, three-component reaction with 1-hydroxy-3H-
benzo[f]chromen-3-ones and 4-hydroxyquinolin-2(1H)-ones, an aromatic aldehyde and 
isonitrile, was developed for the first time, which resulted in a variety of substituted 
functionalized benzo[f]furo[3,2-c]chromen-4-(5H)-ones and furo[3,2-c]quinolin-4-(5H)-ones. 
 
Scheme 14 
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Samanta et.al 19 have developed observed a remarkable solvent effect on one-pot reaction 
of 4-hydroxycoumarin derivatives with (E)-3-aryl-substituted-2-nitroprop-2-enols and it was 
used for expeditious synthesis of highly substituted furo/pyrano[3,2-30 c]chromenes, by 
choosing water or DMSO as a solvent. 
 
Scheme 15 
In 2007, Hu et al.20 have developed a new one-pot cascade reaction for regioselective 
synthesis of furo[3,2-c]coumarins. Herein, authors reported a highly efficient, acid-promoted and 
regioselective one-pot reaction to construct furo[3,2-c]coumarins by addition–cyclization–
oxidation. 
 
Scheme 16 
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3.3 Results and Discussion 
The challenges led us to examine a direct synthetic route to access NAI precursors 
and their further efficient transformations through a cascade process. The acid catalyzed 
reactions of NAI salts well explored in the literature, these transformations mainly involved 
the generation of cationic NAI ions in the presence of excess strong acid. As per the literature 
survey, these type of conditions lead to the formation of dicationic species are called super 
electrophiles, which can be explored in further transformations with suitable nucleophiles.1 
Recently, we have developed an iminium induced one-pot double annulation cascade 
strategy for the synthesis of dihydroisoquinolinium salts.21 Inspired by this work and our 
continuing interest in the development of metal-free and green strategies for the synthesis of 
biologically important heterocyclic compounds,22 herein, we report a novel super-acid-
promoted tandem cyclization strategy to synthesize diversified fully substituted Oxazoles and 
Furocoumarins from readily available starting materials via insituly generated exocyclic NAI 
precursor in one pot. The development of a straightforward method to access the above 
mentioned privileged scaffolds via insitu generation of NAI precursors would be of great 
importance. 
At first, we envisaged to design NAI precursor by cross dehydrogenative coupling 
(CDC) of amines and phenylglyoxals, followed by selective reduction (Scheme 17). 
 
Scheme 17. Designed Strategy for the Synthesis of NAI, Oxazoles and Furocoumarins 
Accordingly, we carried out the reaction with phenylglyoxal 46 and 2-pyrrolidinone 
47 for the synthesis of α-ketoamide 48 under conditions developed in our previous CDC 
strategy.23 Surprisingly, we isolated our desired α-hydroxyl β-keto amide 49 (NAI precursor) 
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instead of α-ketoamide 48 after prolonged reaction time, albeit in very poor yield 15% (Table 
1, entry 1). This interesting result motivated us to improve the yield of the desired product. 
Then we carried out the reactions at various temperatures, which resulted no much 
improvements in the yield of product 49. We have also screened other metal catalysts instead 
of Iodine. Unfortunately, all these reactions led to the formation of mixture of products 48 & 
49 (Table 1, entries 5-12). Without losing hope, we have checked the reaction under catalyst 
free conditions, surprisingly it furnished the desired compound 49 in 40% yield (Table 1, 
entry 13). When we performed the reaction in the absence of catalyst, base and solvent, to our 
delight, the desired product obtained with excellent yield i.e. 98% within minutes (Table 1, 
entry 14).  
Table 1. Optimization of the reaction conditions for NAI precursor 49a 
 
entry catalyst 
(equiv.) 
base 
(equiv.) 
solvent Temp 
(oC) 
Time 
(h) 
yield 
(%)b 
3aa 
yield 
(%)b 
A 
1 Iodine (1.5) K2CO3 
(2.0) 
Toluene rt 24 0 15 
2 Iodine (1.5) K2CO3 
(2.0) 
Toluene 60 24 0 22 
3 Iodine (1.5) K2CO3 
(2.0) 
Toluene 80 24 - - 
4 Iodine (1.5) K2CO3 
(2.0) 
DMF 80 24 - - 
5 CuBr2 (0.2) K2CO3 
(2.0) 
Toluene rt 24 30 10 
6 FeBr2 (0.2) K2CO3 
(2.0) 
DCE rt 24 20 20 
7 CuI (0.2) K2CO3 
(2.0) 
Toluene rt 24 10 22 
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8 Cu(OAc)2 
(0.2) 
K2CO3 
(2.0) 
Toluene 50 24 20 30 
9 Cu(OAc)2 
(0.2) 
K2CO3 
(2.0) 
Toluene 60 24 32 36 
10 Cu(OAc)2 
(0.2) 
K2CO3 
(2.0) 
Toluene 70 24 40 42 
11 Cu(OAc)2 
(0.2) 
K2CO3 
(2.0) 
Toluene 70 24 50 32 
12 Cu(OAc)2 
(0.2) 
K2CO3 
(2.0) 
Toluene 80 24 60 20 
13 - K2CO3 
(2.0) 
Toluene 80 24 - 40 
14 - - - 80 10 
min 
0 98 
aReaction conditions: 46 (1.0 equiv), 47 (1.1 equiv). bIsolated yields after column 
chromatography. 
Having this catalyst and solvent-free conditions for NAI precursor 49 in hand, our 
attention was turned towards the utilization of it for the synthesis of biologically active 
molecules.  
Keeping this in mind firstly we hypothesized to synthesize fully substituted Oxazole 
derivatives by using nitriles through 3+2 cycloaddition under Metal-free conditions. 
Accordingly, to test our hypothesis, first we generated the NAI precursor 49 by the 
reaction of phenylglyoxal 46 with 2-pyrrolidinone 47 under standard conditions, which could 
subsequently use as the model substrate without isolation. 
Then the model reaction was performed by the addition of CH3CN 52 in the presence 
of Brønsted acid (methyl sulfonic acid MsOH), afforded the expected product 50a albeit in 
40% yield along with by-product bisamide 53 in 20% yield (Table 2, entry 1). The formation 
of by-product might be due to the release of H2O in the reaction. Encouraged by this 
preliminary result, we further screened with various Brønsted and Lewis acids at different 
temperatures in DCE as a solvent and the results were summarized in Table 2. From the 
results we understand that the nature of acid and temperature had a significant effect on the 
outcome of the reaction. Among the various Brønsted acids screened, only triflic acid 
effectively promoted the desired product (Table 2, entries 1-11). In order to evaluate the 
effects of acidity we screened with different equivalents of triflic acid under various 
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temperatures, finally, 5.0 equiv of triflic acid was found to be effective at 130 °C to afford the 
desired product 50a in excellent yield 91%. (Table 2, entry 11). The results revealed that the 
employment of Lewis acids was not useful (Table 2, entries 16 to 20). 
 
Table 2. Optimization studies for the synthesis of Oxazole 50aa 
 
 
entry acid (equiv) solvent temp Isolated yield (%)  
50a 53 
1 MsOH (5.0) DCE rt 40 20 
2 MsOH (5.0) DCE rt 30 47 
3 MsOH (5.0) DCE 80 °C 48 9 
4 MsOH (5.0) DCE 100 °C 55 4 
5 MsOH (5.0) DCE 120 °C 71 Nd 
6 MsOH (5.0) DCE 120 °C 61 Nd 
7 MsOH (5.0) DCE 130 °C 75 Nd 
8 TfOH (5.0) DCE 120 °C 81 Nd 
10 TfOH (4.0) DCE 130 °C 75 Nd 
11 TfOH (5.0) DCE 130 °C 91 Nd 
12 TfOH (6.0) DCE 130 °C 85 Nd 
13 HCl (5.0) DCE 130 °C Nd Nd 
14 H2SO4 (5.0) DCE 130 °C Nd
 Nd 
15 CH3COOH (5.0) DCE 130 °C Nd Nd 
16 FeCl3 (0.2) DCE 130 °C Nd Nd 
17 AlCl3 (0.2) DCE 130 °C Nd
 Nd 
18 InCl3 (0.2) DCE 130 °C Nd Nd 
19 Sc(Otf)3 (0.2) DCE 130 °C Nd
 Nd 
20 Bf3OEt2 (0.2) DCE 130 °C Nd
 Nd 
aReaction conditions: 1st step: 46 (1.0 mmol), 47 (1.1 mmol), 80 °C, 10 min, 2nd step: DCE 
dry solvent (0.25 M), 52 (1.1 mmol), TfOH (5 mmol), 130 °C, 2 h.  bIsolated yields after 
column chromatography, Nd = not detected.  
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After having the optimized conditions in hand, we have explored the substrate scope 
of the present protocol (Table 3). Arylglyoxals bearing electron-neutral (50a, 50b & 50c), 
electron-rich (50d) and electron-deficient (50e-50k) substituents were smoothly converted to 
the corresponding oxazoles with moderate to very good yields. Interestingly, halo-substituted 
(50j-50n) arylglyoxals were also found to furnish the desired products with good yields (66-
86%), which would provide possibilities for further functionalization. Pleasingly, 2-
oxazolidinone in place of 2-pyrrolidinone were also found to furnish the desired products 
with very good yields (50g, 50h, 50m & 50n). 
Next we checked the reactivity of strong electron withdrawing group (-NO2) in the 4
th 
position of arylglyoxal unit (Table 3, 50s & 50t), unfortunately in both the examples we got 
the both oxazole and bisamide products, after prolonged reaction hours also we didn’t 
observe the complete conversion of bisamide to oxazole products. We achieved the less 
oxazole product yields in both 50s & 50t cases (26% & 32%). 
 
Table 3. Scope of the synthesis of various fully substituted oxazolesa 
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aReaction conditions: 1st step: 46 (1.0 mmol), 54 (1.1 mmol), 80 °C, 10-20 min, 2nd step: 
DCE dry solvent (0.25 M), 52 (1.1 mmol), TfOH (5 mmol), 130 °C, for 2-3 h.  b Isolated 
yields, after column chromatography.  
In order to expand the molecular library of polyfunctional oxazole derivatives, we 
extended it to the heteroaryl nitriles, like 2-cyanopyridines, for the synthesis of valuable bis-
hetero cycles those are pyrid-oxazoles skeletons as shown in table 3. In this transformations, 
2-cyanopyridine is reacted smoothly with NAI intermediates generated from arylglyoxals and 
2-oxazolidinone or 2-pyrrolidinone to afford the desired products from good to excellent 
yields (Table 3, 50o-50r). 
After successfully synthesis of fully substituted Oxazoles, further our attention was 
turned towards the synthesis of Furocoumarins. Accordingly, the new protocol was further 
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demonstrated by using 4-hydroxy-2H-chromen-2-one as carbon-nucleophile (Table 4). 
Arylglyoxals with electron-ne utral (56a & 56g), electron rich (56d & 56e) and electron-
deficient (56b, 56h, 56f & 56c) substituents were smoothly transformed into the 
corresponding privileged Furocoumarine under the optimized conditions with very good 
yields (Table 4).  
Table 4. Scope of the Synthesis of Furocoumarins 
 
aReaction conditions: 1st step: 46 (1.0 mmol), 47 (1.1 mmol), 80 °C, 10-20 min, 2nd step: 
DCE dry solvent (0.25 M), 55 (1.1 mmol), TfOH (5 mmol), 80 °C, 1-2 h.  bIsolated yields, 
after column chromatography. 
To gain insight into the reaction mechanism, preliminary control experiments were 
conducted. When the reaction was performed in the absence of acid, no desired product was 
formed, indicating that the presence of acid is crucial for this reaction (Scheme 18a). Since 
the present reaction requires excess acid to effect the transformations (standard conditions), 
we hypothesized that the reaction might be proceed through proto-solvation of N-
acyliminium ion B (Scheme 18b). Accordingly, we have performed the reaction with weak 
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nucleophile i.e. benzene instead of acetonitrile 52. To our delight, we could have isolated the 
benzene trapped product C with 80% yield.  
This result suggested that a proto-solvated iminium intermediate B was most likely 
involved in this reaction. To know further possible intermediates as per our observations 
during optimization of reaction conditions (Table 2, entry1 and 3), we assumed that either 
bisamide or nitrelium ion may be the reaction intermediates after attacking of nitrile 52 to 
intermediate B to afford the oxazole 50a. Accordingly, we have subjected the bisamide 53 to 
standard conditions, which resulted in oxazole 4a with excellent yield as we expected 
(Scheme 18c). 
Scheme 18. Mechanistic Experiments 
 
Based on the above observed products and previous literature reports,3 a plausible 
mechanism was proposed for the present reaction (Scheme 19). Initially the NAI precursor 49 
would form the iminium intermediate B under acidic conditions. Then cyclization was occur 
by two conceivable paths: In path a, acetonitrile would attack proto solvated iminium 
intermediate B to afford nitriliumion I, which then would neutralized by the adjacent 
carbonyl oxygen to furnish the final product 50a. In path b, the nitriliumion I would be 
  
116 
 
neutralized by the water molecule to form the bisamide 53, which would further undergo 
dehydration -cyclization to furnish the final product 50a.  
 
Scheme 19. Plausible reaction mechanism for 50a 
 
 
Scheme 20. Gram Scale Synthesis 
After having successfully developed super acid promoted a one-pot strategy for the 
synthesis of fully substituted oxazoles and furocoumarin scaffolds. We envisaged to examine 
the scalability of the process. Consequently, we have performed the reaction on the 2g scale 
and isolated the product 50a as a white solid with very good yield (86%) after column 
purification (Scheme 20). The scalability of our protocol should prove industrially applicable.    
Photophysical Properties of Pyrid-oxazoles and Furocoumarins 
After having synthesized compounds in hand, we were keen to study the UV-visible 
and fluorescence characteristics of chosen Pyrid-oxazoles and Furocoumarins. The UV-
visible spectra of compounds 50r, 50p, 50q & 50o in ethanol (EtOH) exhibited maximum 
absorption wavelength (λmax) at 320 nm and the data are summarized in Table 5 and Figure 4.  
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Figure 4. Fluorescence (a) and Absorption (b) spectra of Pyrid-oxazoles 50o-50r in ethanol 
at room temperature. 
Table 5. UV-Vis Absorption and Fluorescence Emission Properties of Compounds 4o-4ra,b 
entry compou
nd 
A λmax (abs) in 
nma 
B λmax (abs) in 
nma 
C λmax (abs) in nma λem in nmb 
1 50r 206 262 320 464 
2 50p 205 225 320 420 
3 50q 206 226 320 414 
4 50o 205 227 320 422 
aUV-visible absorption wavelengths, bEmission wavelengths at room temperature at 
concentration of 1x10-3 M in EtOH. 
The fluorescence spectra of pyrid-oxazole compounds showed emission wavelength 
(λem) at 414-464 nm (Table 5). The presence of more electronegative atom (Fluorine) and 
strong electron withdrawing group (trifluoromethyl group) in the para position of the 
aromatic ring in compounds 50r, 50p & 50q showed the less fluorescence intensity (Figure 
4). 
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Figure 5. Fluorescence (c) and Absorption (d) spectra of Furocoumarins 56a-56h in ethanol 
at room temperature. 
Similarly, we have also recorded the UV-visible and fluorescence spectra of Furocoumarins 
(56a-56h) in EtOH. The UV-visible spectra of compounds 56a-56h (Figure 5d) exhibited 
maximum absorption wavelengths at 205-210 nm (Table 6). The absorption bands shift 
values indicated that there was no significance difference with regardless of substituents 
presence in the aromatic rings, and an increase in absorption intensity in the compounds 56f, 
56e and 56a was observed. The fluorescence properties of the compounds 56a-56h (Figure 
5c) displayed emission wavelength (λem) at 396-449 nm (Table 6). Among all the compounds, 
56g, 56h and 56f showed an increase in fluorescence intensity along with an increase of the 
electron with drawing properties of the substituent in aromatic ring were also observed. 
Table 6. UV-Vis Absorption and Fluorescence Emission Properties of Compounds 7a-7ha,b 
entry compound 
A λmax (abs) in 
nma 
B λmax (abs) in 
nma 
 C λmax (abs) in 
nma λem (nm)
b 
1 56a 210 300 328 412 
2 56b 207 294 330 415 
3 56d 208 314 340 449 
4 56c 208 300 329 417 
5 56g 205 302 338 404 
6 56h 205 301 337 408 
7 56e 211 286 345 436 
8 56f 210 301 328 396 
 
aUV-visible absorption wavelengths, bEmission wavelengths at room temperature at 
concentration of 1x10-3 M in EtOH.  
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3. 4. Conclusion 
 In conclusion, we have described a concise, one-pot route to Oxazoles and 
Furocoumarins through N-acyliminium ion as a key intermediate. The key step in this 
transformation involves insitu generation of NAI precursor under catalyst and solvent 
free conditions, and their further transformations promoted by superacid in the same 
pot. The experimental evidence for the involvement of proto-solvated novel exocyclic 
N-acyliminium ion in superacid promoted reaction has been presented. We have also 
investigated the photophysical properties of Furocoumarins and Pyrid-oxazole 
derivatives, and these studies reveal that possible applications for the discovery of 
highly fluorescent probes. 
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3.5 Experimental section 
General Information 
IR spectra were recorded on a FTIR spectrophotometer. 1H NMR spectra were 
recorded on 400 MHz spectrometer at 295 K in CDCl3; chemical shifts (δ ppm) and coupling 
constants (Hz) are reported in standard fashion with reference to either internal standard 
tetramethylsilane (TMS) (δH = 0.00 ppm) or CHCl3 (δH = 7.25 ppm). 13C NMR spectra were 
recorded on 100 MHz spectrometer at 25 °C in CDCl3; chemical shifts (δ ppm) are reported 
relative to CHCl3 [δC = 77.00 ppm (central line of triplet)]. In the 1HNMR, the following 
abbreviations were used throughout: s = singlet, d = doublet, t = triplet, q = quartet, qui = 
quintet, dd = doublet of doublets, m = multiplet and br s. = broad singlet. The assignment of 
signals was confirmed by 1H, 13C CPD, and DEPT spectra. High-resolution mass spectra 
(HR-MS) were recorded using Q-TOF multimode source. Melting points were determined on 
an electro thermal melting point apparatus and are uncorrected. Other reagents were 
purchased as reagent grade and used without further purification. All dry solvents were used. 
DCE and DCM was dried over CaH2. 
Reactions were monitored by TLC on silica gel using a combination of petroleum 
ether and ethyl acetate as eluents. All reactions were performed under air atmosphere in 
standard glassware, heated at 80 °C for 3 h before use. Solvents were distilled prior to use; 
petroleum ether with a boiling range of 40 to 60 ˚C was used. Organic solutions were 
concentrated by rotary evaporation under vacuum. Acme’s silica gel (60–120 mesh) was used 
for column chromatography (approximately 20 g per one gram of crude material).  
General procedure (GP-I) for the synthesis of Phenylglyoxals (46a to 46h)  
All the phenylglyoxals were synthesized according to the literature procedures,12 to a 
50 mL two-neck round bottom flask SeO2 (4.99 g, 45.0 mmol), H2O (0.76g, 42.5 mmol) and 
1,4-dioxane (25.0 ml) were added and fixed a condenser. Then the mixture was heated to 
reflux with stirring until the solid was dissolved. Then, substituted aryl ketones (25.0 mmol) 
was added to the solution. The reaction mixture was allowed to reflux for 2 to 6 h. After the 
reaction was completed (monitoring by TLC), the reaction mixture was cooled to room 
temperature and filtered through a Celite pad. The Celite pad was washed several times with 
diethyl ether. The combined filtrate was evaporated on a rotary evaporator to afford the crude 
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product. The crude residue was purified through a silica gel column using petroleum 
ether/ethyl acetate (8:2) as eluent. 
General procedure 2: for the synthesis of Oxazoles (50a to 50r) 
Phenylglyoxal 46a (1 mmol) was taken in a dried 10 mL round bottom flask, and 2-
pyrrolidinone 47 (1.1 mmol) was added and the reaction mixture was stirred under neat 
conditions at 80oC temperature for 10 min to 20 min. After the formation of intermediate 49 
(confirmed by TLC), then added DCE (2 mL) and nitrile partner 52 (1.1 mmol), followed by 
addition of Triflic acid (5 mmol) then the reaction flask was connected to a condenser 
circulating with cold water and kept at 130 oC in oil bath. The progress of the reaction was 
monitored by TLC till the reaction is completed (2-3 h). The reaction mixture was quenched 
by addition of saturated solution of NaHCO3 and extracted with ethyl acetate, dried over 
MgSO4, and concentrated in vacuo. The residue was purified through a silica gel column 
using petroleum ether/ethyl acetate (8:2) as eluent. All the compounds (50a to 50r) were 
confirmed by FTIR, 1H NMR, 13C NMR and HR-MS spectral analyses. 
Large Scale procedure for the synthesis of Oxazole (50a) 
Phenylglyoxal 46 (14.91 mmol, 2g) was taken in a dried 100 mL round bottom flask, 
and 2-pyrrolidinone 47 (16.40 mmol, 1.395g) was added and the reaction mixture was stirred 
under neat conditions at 80 oC temperature for 10 min to 20 min, after the formation of 
intermediate 49 (confirmed by TLC), then added DCE 40mL and triflicacid (74.55 mmol, 
11.18g) was added and RB connected to the condenser circulating with cold water then the 
reaction setup was shifted to 130 oC, oil bath after 2h, after completion of the reaction 
confirmed by TLC then the reaction mixture was quenched with saturated sodium 
bicarbonate solution and extracted with ethyl acetate, dried over MgSO4, and concentrated in 
vacuo. The residue was purified through a silica gel column using petroleum ether/ethyl 
acetate (8:2) as eluent. Final compound was isolated with 86% yield, 3.1g,  
General procedure 3: for the synthesis of Furocoumarins (56a to 56h) 
Phenyl glyoxal 46 (1 mmol) was taken in a dried 10 mL round bottom flask, and 2-
pyrrolidinone 47 (1.1 mmol) was added and the reaction mixture was stirred under neat 
conditions at 80 oC temperature for 10 min to 20 min. After the formation of intermediate 49 
(confirmed by TLC), then added DCE (2 mL) and 4-Hydroxycoumarin partner 6, followed by 
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addition of Triflic acid (5 mmol) then the reaction was kept at 80 oC. The progress of the 
reaction was monitored by TLC till the reaction is completed (1-2 h). The reaction mixture 
was quenched by addition of saturated solution of NaHCO3 and extracted with ethyl acetate, 
dried over MgSO4, and concentrated in vacuo. The residue was purified through a silica gel 
column using petroleum ether/ethyl acetate (8:2) as eluent. All the compounds 56a to 56h 
were confirmed by FTIR, 1H NMR, 13C NMR and HR-MS spectral analysis.  
 
1-(2-methyl-5-phenyloxazol-4-yl) pyrrolidin-2-one (50a) 
Physical state  : white solid 
Yield   : 91%  
Mp   : 85-87 ˚C 
IR (MIR-ATR, 4000–600 cm-1) νmax = 3054, 2926, 1706, 1628, 1585, 1494, 1412, 1262, 
1225, 1018, 913, 835, 729, 692, 591, 546. 
1H NMR (400 MHz, CDCl3): δ 7.58 - 7.51 (m, 2H), 7.43 - 7.37 (m, 2H), 7.34 - 7.28 (m, 1H), 
3.80 (t, J = 7.1 Hz, 2H), 2.59 (t, J = 8.1 Hz, 2H), 2.50 (s, 3 H), 2.24 (quin, J = 7.6 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 175.2, 159.2, 143.0, 130.5, 128.7, 128.3, 127.5, 124.9, 
48.8, 31.1, 19.0, 14.3. 
HR-MS (ESI-TOF) m/z: [M+H]+ calcd for [C14H15N2O2]
+ 243.1128; Found 243.1129.  
 
1-(2-benzyl-5-phenyloxazol-4-yl)pyrrolidin-2-one (50b) 
Physical state  : Light yellow solid 
Yield   :73%  
Mp   : 87-89 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3465, 3060, 3030, 2923, 1706, 1625, 1572, 1493, 
1451, 1409, 1256, 1222, 1170, 1070, 1020, 912, 835, 766, 729, 692, 549. 
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1H NMR (400 MHz, CDCl3): δ 7.53 - 7.48 (m, 2 H), 7.40 - 7.32 (m, 6 H), 7.32 - 7.23 (m, 2 
H), 4.12 (s, 2 H), 3.83 - 3.77 (m, 2 H), 2.56 (t, J = 8.1 Hz, 2 H), 2.21 (quin, J = 7.6 Hz, 2 H). 
13C{1H}NMR(100 MHz, CDCl3): δ 175.0, 160.5, 143.3, 135.0, 130.7, 128.9, 128.8, 128.7, 
128.4, 127.5, 127.2, 125.0, 77.5, 77.4, 77.2, 76.8, 48.8, 35.0, 31.2, 19.0.  
HR-MS (ESI-TOF) m/z: [M+H]+ calcd for [C20H19N2O2]
+  319.1441; Found 319.1442. 
 
1-(2-(3-bromopropyl)-5-phenyloxazol-4-yl) pyrrolidin-2-one (50c):  
Physical state  : White solid 
Yield   :88% 
Mp   : 138-140 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3059, 2961, 1709, 1628, 1600, 1578, 1445, 1261, 
1227, 1178, 1021, 915, 836, 767, 692. 
1H NMR (400 MHz, CDCl3): δ 7.54 (d, J = 7.3 Hz, 2H), 7.40 (t, J = 7.6 Hz, 2H), 7.35 - 7.29 
(m, 1H), 3.81 (t, J = 7.1 Hz, 2H), 3.55 (t, J = 6.4 Hz, 2H), 2.99 (t, J = 7.3 Hz, 2H), 2.59 (t, J = 
8.1 Hz, 2H), 2.37 (quin, J = 6.8 Hz, 2H), 2.25 (quin, J = 7.6 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 175.2, 160.9, 143.1, 130.5, 128.7, 128.5, 128.4, 127.4, 
125.0, 48.8, 32.4, 31.1, 29.5, 26.9, 18.9. 
HR-MS (ESI-TOF) m/z: [M+H]+ calcd for [C16H18BrN2O2]
+ 349.0546; Found 349.0547. 
 
Methyl 2-(5-(4-fluoro-3-methylphenyl)-4-(2-oxopyrrolidin-1-yl)oxazol-2-yl)acetate 
(50d): 
Physical state  : Pale Yellow solid 
Yield   :78% 
Mp   : 150-151 ˚C 
  
124 
 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3046, 2936, 2836, 1703, 1601, 1513, 1460, 1416, 
1262, 1235, 1212, 1171, 1140, 1020, 924, 860, 810, 765,731,698,623,582. 
1H NMR (400 MHz, CDCl3): δ  7.12 (s, 1H), 7.1 (d, J = 2 Hz, 1H), 6.89 (d, J = 7.8 Hz, 1H), 
4.4 (s, 2H), 3.88 (s, 6H), 3.8 (t, J = 7.1, 2H),  2.5 (t, J = 8.3 Hz, 2H), 2.2 (q, J = 7.6, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ  175.0, 155.7, 149.7, 149.0, 144.7, 130.1, 119.7, 118.7, 
111.3, 108.7, 55.9, 48.8, 31.1, 20.5, 19.0.  
HR-MS (ESI-TOF) m/z: [M+H] + calcd for [C16H18BrN2O4]
 + 381.0444; Found 381.0447. 
 
Single crystal X-ray structure data of compound 50d (CCDC 1835405): Thermal 
ellipsoids are drawn at 50% probability level. 
 
 
 
 
 
 
 
 
 
Identification code exp_5510 
Empirical formula C16H17BrN2O4 
Formula weight 381.23 
Temperature/K 293 
Crystal system Triclinic 
Space group P-1 
a/Å 9.1144(10) 
b/Å 9.4623(10) 
c/Å 10.9816(12) 
α/° 79.346(9) 
β/° 72.139(10) 
γ/° 65.185(11) 
Volume/Å3 816.48(17) 
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Z 2 
ρcalcg/cm3 1.5505 
μ/mm-1 3.628 
F(000) 387.7 
Crystal size/mm3 0.08 × 0.06 × 0.05 
Radiation Cu Kα (λ = 1.54184) 
2Θ range for data collection/° 8.48 to 142.3 
Index ranges -11 ≤ h ≤ 10, -11 ≤ k ≤ 8, -13 ≤ l ≤ 12 
Reflections collected 5203 
Independent reflections 3025 [Rint = 0.0303, Rsigma = 0.0465] 
Data/restraints/parameters 3025/0/207 
Goodness-of-fit on F2 1.105 
Final R indexes [I>=2σ (I)] R1 = 0.0452, wR2 = 0.1345 
Final R indexes [all data] R1 = 0.0625, wR2 = 0.1441 
Largest diff. peak/hole / e Å-3 0.49/-0.73 
 
 
2-(5-(3-nitrophenyl)-4-(2-oxopyrrolidin-1-yl)oxazol-2-yl)benzaldehyde (50e):  
Physical state  : White solid 
Yield   :76% 
Mp   : 234-237 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3078, 2922,  2852, 1701, 1605, 1526, 1410, 1348, 
1259, 1204, 1166, 1097, 1015, 835, 804, 739,721, 693. 
1H NMR (400 MHz, CDCl3): δ  10.02 (s, 1 H), 8.37 (t, J = 2.0 Hz, 1 H), 8.22 - 8.16 (m, J = 
8.3 Hz, 2 H), 8.11 (ddd, J = 1.0, 2.0, 8.3 Hz, 1 H), 7.98 - 7.90 (m, 2 H), 7.85 (td, J = 1.3, 8.1 
Hz, 1 H), 7.55 (t, J = 8.1 Hz, 1 H), 3.98 (t, J = 7.1 Hz, 2 H), 2.66 - 2.55 (m, 2 H), 2.30 (quin, 
J = 7.6 Hz, 2 H)  
13C{1H}NMR (100 MHz, CDCl3) : δ  191.4, 174.5, 158.2, 148.4, 140.8, 137.7, 134.5, 131.4, 
130.9, 130.2, 129.7, 129.1, 127.0, 122.9, 120.3, 77.4, 77.0, 76.7, 48.6, 31.2, 19.0. 
 HR-MS (ESI-TOF) m/z: [M+H]+ calcd for [C20H16N3O5]
+378.1084; Found: 378.1093. 
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1-(2-(bromomethyl)-5-(3-nitrophenyl) oxazol-4-yl)pyrrolidin-2-one (50f):  
Physical state  : Light Yellow solid 
Yield   :81% 
Mp   : 128-130 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3041, 2984, 2888, 1709, 1611, 1524, 1405, 1348, 
1324, 1255, 1207, 1109, 920, 816, 766, 739, 720, 674, 588. 
1H NMR (400 MHz, CDCl3) : δ 8.36 (s, 1H), 8.18 (dd, J = 1.2, 8.1 Hz, 1H), 7.84 (d, J = 7.8 
Hz, 1H), 7.60 (t, J = 8.1 Hz, 1H), 4.48 (s, 2H), 3.97 (t, J = 7.1 Hz, 2H), 2.63 (t, J = 8.1 Hz, 
2H), 2.32 (quin, J = 7.5 Hz, 2H). 
13C{1H} NMR (100 MHz, CDCl3): δ 174.3, 157.4, 148.3, 141.1, 133.1, 130.9, 129.6, 128.9, 
123.0, 120.4, 48.5, 31.1, 19.9, 19.0.  
HR-MS (ESI-TOF) m/z: [M+H]+ calcd for [C14H13BrN3O4]
+366.0084; Found 366.0090. 
 
3-(2-methyl-5-(3-nitrophenyl) oxazol-4-yl)oxazolidin-2-one (50g): 
Physical state  : Yellow solid 
Yield   :86% 
Mp   : 126-127 ˚C 
 IR (MIR-ATR, 4000–600 cm-1): νmax = 3648, 3087, 2923, 2854, 1754, 1632, 1582, 1526, 
1481, 1415, 1385, 1347, 1311, 1253, 1211, 1183, 1117, 1054, 1034, 983, 945, 898, 869, 807, 
761, 731, 678, 597. 
1H NMR (400 MHz, CDCl3): δ 8.45 (t, J = 1.7 Hz, 1H), 8.22 - 8.10 (m, 1H), 7.89 (d, J = 7.8 
Hz, 1H), 7.60 (t, J = 8.1 Hz, 1H), 4.62 (t, J = 8.1 Hz, 2H), 4.13 (t, J = 7.8 Hz, 2H), 2.55 (s, 
3H). 
13C{1H}NMR (100 MHz, CDCl3): δ 160.2, 155.8, 148.4, 140.2, 131.9, 130.7, 129.8, 129.0, 
122.7, 119.9, 63.1, 45.8, 14.3. 
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HR-MS (ESI-TOF) m/z: [M+ Na]+ calcd for [C13H11N3NaO5]
+ 312.0591; Found 312.0593.  
 
3-(2-(2-bromoethyl)-5-(3-nitrophenyl) oxazol-4-yl)oxazolidin-2-one (50h): 
Physical state  : Light Yellow solid 
Yield   :73% 
Mp   : 132-134 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3086, 2980, 2920, 1757, 1631, 1577, 1529, 1482, 
1416, 1348, 1252, 1213, 1114, 1032, 983, 945, 808, 732, 678, 560. 
1H NMR (400 MHz, CDCl3):  δ 8.45 (s, 1H), 8.18 (d, J = 8.3 Hz, 1H), 7.90 (d, J = 7.8 Hz, 
1H), 7.61 (t, J = 7.8 Hz, 1H), 4.63 (t, J = 7.8 Hz, 2H), 4.16 (t, J = 7.8 Hz, 2H), 3.76 (t, J = 6.8 
Hz, 2H), 3.43 (t, J = 6.8 Hz, 2H). 
13C{1H} NMR (100 MHz, CDCl3): δ 160.1, 155.6, 148.4, 140.4, 132.1, 130.9, 129.8, 128.8, 
122.9, 120.1, 63.2, 45.7, 32.0, 26.6.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C14H13BrN3O5]
+ 382.0033; Found: 382.0040.  
 
3-(2-benzyl-5-(3-nitrophenyl) oxazol-4-yl)oxazolidin-2-one (50i): 
Physical state  : Light brown solid 
Yield   :70% 
Mp   : 148-151 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3062, 2986, 2918, 1756, 1630, 1573, 1527, 1481, 
1413, 1347, 1252, 1211, 1183, 1116, 1052, 1032, 982, 945, 898, 869, 806, 728, 696, 566. 
1H NMR (400 MHz, CDCl3): δ  8.41 (t, J = 1.7 Hz, 1H), 8.14 (dd, J = 1.0, 8.3 Hz, 1H), 7.86 
(d, J = 7.8 Hz, 1H), 7.57 (t, J = 8.1 Hz, 1H), 7.40 - 7.34 (m, 4 H), 7.33 - 7.28 (m, 1H), 4.60 (t, 
J = 8.1 Hz, 2H), 4.16 (s, 2H), 4.15 - 4.10 (m, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 161.6, 155.6, 148.4, 140.3, 134.4, 132.1, 130.8, 129.7, 
128.9, 128.9, 127.5, 122.8, 120.0, 63.1, 45.7, 34.9.  
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HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C19H16N3O5]
+ 366.1084; Found 366.1087. 
 
1-(5-(4-fluorophenyl)-2-methyloxazol-4-yl)pyrrolidin-2-one (50j) 
Physical state  : White solid 
Yield   :86% 
Mp   : 78-80 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3747, 3066, 2926, 2891, 1703, 1631, 1589, 1509, 
1411, 1299, 1260, 1225, 1158, 1092, 1036, 1010, 957, 915, 836, 728, 606, 579. 
1H NMR (400 MHz, CDCl3) δ : 7.54 - 7.47 (m, 2H), 7.12 - 7.05 (m, 2H), 3.80 (t, J = 7.1 Hz, 
2H), 2.58 (t, J = 8.3 Hz, 2H), 2.48 (s, 3H), 2.28 - 2.18 (m, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 175.1, 163.7, 161.2, 159.1, 142.1, 130.2, 127.0, 126.9 (d, 
J = 8), 123.9 (d, J = 4), 115.9 (d, J = 22), 48.8, 31.1, 19.0, 14.2.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C14H14FN2O2]
+ 261.1034; Found: 261.1035. 
 
3-(5-(4-bromophenyl)-2-(3-bromopropyl)oxazol-4-yl)oxazolidin-2-one (50k): 
Physical state  : Light Yellow solid 
Yield   :83% 
Mp   : 128-131 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3059, 2921, 2851, 1710, 1628, 1580, 1490, 1414, 
1260, 1072, 1007, 913, 827, 728. 
1H NMR (400 MHz, CDCl3): δ 7.53 (d, J = 8.8 Hz, 2H), 7.39 (d, J = 8.3 Hz, 2H), 3.83 (t, J = 
6.8 Hz, 2H), 3.54 (t, J = 6.4 Hz, 2H), 2.98 (t, J = 7.3 Hz, 2H), 2.59 (t, J = 8.1 Hz, 2H), 2.37 
(quin, J = 6.8 Hz, 2H), 2.25 (quin, J = 7.6 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ  174.9, 161.2, 141.9, 131.9, 131.0, 126.5, 126.4, 122.4, 
48.7, 32.3, 31.2, 29.4, 26.8, 18.9. 
HR-MS (ESI-TOF) m/z: [M+ Na]+ calcd for [C16H16Br2N2NaO2]
+ 448.9471; Found 
448.9464. 
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methyl 2-(5-(4-fluoro-3-methylphenyl)-4-(2-oxopyrrolidin-1-yl)oxazol-2-yl)acetate (50l):  
Physical state             : Yellow solid 
Yield   : 83% 
Mp   : 126-128 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 2956, 2893, 1744, 1706, 1630, 1586, 1501, 1413, 
1350, 1254, 1119, 1010, 887, 824, 731, 702, 635, 549. 
1H NMR (400 MHz, CDCl3): δ  7.4 (dd, J = 7.1, 1.7 Hz, 1H), 7.32 (ddd, J = 7.9, 5, 2.2 Hz, 
1H), 7.03 (t, J = 8.8 Hz, 1H), 3.87 (s, 2H), 3.83 (t, J = 7.3 Hz, 2H), 3.77 (s, 3H),  2.57 (t, J = 
8.1 Hz, 2H), 2.29 (s, 3H), 2.28-2.20 (m, 2H). 
13C{1H} NMR (100 MHz, CDCl3): δ 174.9, 167.5, 162.5, 160.0, 154.5, 143.3, 130.3, 128.6, 
128.5, 125.3 (d, J = 18), 124.7, (d, J = 9), 123.28 (d, J = 4), 115.55 (d, J = 24), 52.7, 48.7, 
34.6, 31.1, 18.9, 14.67, 14.64.   
HR-MS (ESI-TOF) m/z: [M+ Na]+ calcd for [C17H17FN2O4]
+ 355.1065; Found 355.1066. 
 
3-(2-benzyl-5-(4-fluoro-3-methylphenyl)oxazol-4-yl)oxazolidin-2-one (50m):  
Physical state  : White solid 
Yield   :68% 
Mp   : 96-98 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3060, 2985, 2922, 1757, 1682, 1574, 1501, 1423, 
1258, 1228, 1171, 1120, 1054, 1033, 982, 948, 795, 757, 716, 640. 
1H NMR (400 MHz, CDCl3): δ 7.42 (dd, J = 1.7, 7.6 Hz, 1H), 7.40 - 7.37 (m, 1H), 7.37 - 7.33 
(m, 4H), 7.32 - 7.25 (m, 1H), 7.03 (t, J = 9.0 Hz, 1H), 4.53 (t, J = 7.8 Hz, 2H), 4.12 (s, 2H), 
4.02 (dd, J = 7.3, 8.8 Hz, 2H), 2.29 (d, J = 1.5 Hz, 3H). 
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13C{1H}NMR (100 MHz, CDCl3): δ 162.6, 160.4, 160.1, 156.3, 143.2, 134.8, 129.4, 128.9, 
128.8, 128.6, 128.5, 127.3, 125.6 (d, J = 17), 124.7 (d, J = 9), 123.0 (d, J = 4), 115.5 (d, J = 
24), 62.9, 46.0, 34.9, 14.7. 
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C20H18FN2O3]
+ 353.1296; Found 353.1303. 
 
3-(2-(3-bromopropyl)-5-(4-fluoro-3-methylphenyl)oxazol-4-yl)oxazolidin-2-one (50n): 
Physical state  : White solid 
Yield   :66% 
Mp   : 118-121 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 2967, 2921, 1755, 1639, 1580, 1502, 1423, 1256, 
1229, 1170, 1119, 1034, 980, 946, 877, 821, 733, 630, 559. 
1H NMR (400 MHz, CDCl3): δ 7.45 (dd, J = 1.5, 7.3 Hz, 1H), 7.43 - 7.34 (m, 1H), 7.05 (t, J = 
8.8 Hz, 1H), 4.56 (dd, J = 7.3, 8.8 Hz, 2H), 4.02 (dd, J = 7.3, 8.8 Hz, 2H), 3.55 (t, J = 6.4 Hz, 
2H), 2.98 (t, J = 7.3 Hz, 2H), 2.41 - 2.32 (m, 2H), 2.31 (d, J = 1.5 Hz, 3H). 
13C{1H} NMR (100 MHz, CDCl3): δ 162.6, 160.7, 160.1, 156.4, 143.0, 129.3, 128.5 (d, J = 
5), 125.7, 125.5, 124.7 (d, J = 8), 123.0 (d, J = 4), 115.7, 115.5, 62.9, 46.0, 32.3, 29.4, 26.8, 
14.7. HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C16H17BrFN2O3]
+383.0401; Found 
383.0396. 
 
3-(5-(4-bromophenyl)-2-(pyridin-2-yl)oxazol-4-yl)oxazolidin-2-one (50o): 
Physical state  : Light green solid 
Yield   :75% 
Mp   : 212-214 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3564, 3364, 2259, 2131, 1746, 1734, 1698, 1649, 
1557, 1540, 1521, 1256, 1045, 1023, 989, 826, 763, 666, 632, 574, 548. 
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1H NMR (400 MHz, DMSO-D6): δ 8.77 (d, J = 4.4 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H), 8.03 
(dt, J = 1.5, 7.8 Hz, 1H), 7.71 (q, J = 8.8 Hz, 4H), 7.59 (dd, J = 4.9, 6.8 Hz, 1H), 4.63 (t, J = 
7.8 Hz, 2H), 4.13 (t, J = 8.1 Hz, 2H). 
13C{1H}NMR (100 MHz, DMSO-D6): δ 157.1, 155.4, 150.1, 144.5, 142.0, 137.7, 132.4, 
131.9, 127.1, 125.8, 125.7, 122.3, 122.2, 63.3, 45.6.  
HR-MS (ESI-TOF) m/z: [M+ Na]+ calcd for [C17H12BrN3NaO3]
+ 407.9954; Found 407.9974. 
 
1-(5-(4-fluorophenyl)-2-(pyridin-2-yl)oxazol-4-yl)pyrrolidin-2-one (50p):  
Physical state  : White solid 
Yield   :88% 
Mp   : 188-191 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3054, 2983, 2891, 1702, 1617, 1587, 1508, 1459, 
1411, 1332, 1258, 1222, 1157, 1111, 1045, 1012, 838, 793, 738, 623, 601. 
1H NMR (400 MHz, CDCl3): δ 8.82 - 8.74 (m, 1H), 8.16 - 8.09 (m, 1H), 7.84 (dt, J = 2.0, 7.8 
Hz, 1H), 7.73 - 7.66 (m, 2H), 7.39 (ddd, J = 1.0, 4.8, 7.5 Hz, 1H), 7.17 - 7.11 (m, 2H), 3.97 
(t, J = 7.1 Hz, 2H), 2.62 (t, J = 7.1 Hz, 2H), 2.29 (quin, J = 7.5 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 175.0, 161.6, 150.3, 145.5, 143.5, 137.0, 127.7 (d, J = 
8), 123.6 (d, J = 4), 122.1, 116.0 (d, J = 22), 48.9, 31.2, 19.0.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C18H15FN3O2]
+ 324.1143; Found 324.1144. 
 
1-(2-(pyridin-2-yl)-5-(4-(trifluoromethyl)phenyl)oxazol-4-yl)pyrrolidin-2-one (50q): 
Physical state  : white solid 
Yield   :92% 
Mp   : 202-205 ˚C 
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IR (MIR-ATR, 4000–600 cm-1): νmax = 3055, 2986, 2895, 1710, 1616, 1460, 1411, 1323, 
1259, 1165, 1117, 1067, 1013, 843, 795, 740, 707, 619. 
1H NMR (400 MHz, CDCl3): δ 8.85 - 8.72 (m, 1H), 8.14 (d, J = 8.3 Hz, 1H), 7.86 (dt, J = 1.5, 
7.8 Hz, 1H), 7.83 - 7.77 (m, 2H), 7.73 - 7.65 (m, 2H), 7.42 (ddd, J = 1.0, 4.9, 7.8 Hz, 1H), 
4.03 (t, J = 7.1 Hz, 2H), 2.64 (t, J = 8.1 Hz, 2H), 2.32 (quin, J = 7.5 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 174.7, 158.0, 150.4, 145.3, 142.3, 137.1, 133.9, 130.7, 
130.3, 130.0, 125.7, 125.6 (d, J = 11), 125.3, 125.2, 122.3, 48.8, 31.3, 19.0.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C19H15F3N3O2]
+ 374.1111; Found 374.1118. 
 
1-(5-(4-fluoro-3-methylphenyl)-2-(pyridin-2-yl)oxazol-4-yl)pyrrolidin-2-one (50r):  
Physical state  : White solid 
Yield   :73% 
Mp   : 162-164 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3055, 2991, 2920, 1756, 1627, 1589, 1502, 1423, 
1331, 1227, 1120, 1032, 949, 795, 757, 716, 640. 
1H NMR (400 MHz, CDCl3): δ 8.75 (d, J = 4.9 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H), 8.02 (t, J = 
7.8 Hz, 1H), 7.68 (d, J = 7.3 Hz, 1H), 7.64 - 7.51 (m, 2H), 7.30 (t, J = 9.0 Hz, 1H), 4.62 (t, J 
= 7.8 Hz, 2H), 4.10 (t, J = 7.8 Hz, 2H), 2.33 (s, 3H). 
13C{1H} NMR (100 MHz, CDCl3 & DMSO-D6): δ 162.0, 159.6, 156.7, 155.7, 150.0, 144.5, 
142.8, 137.7, 131.4, 128.5 (d, J = 4), 125.6, 125.3, 125.1 (d, J = 5), 125.0, 122.8 (d, J = 6), 
122.2, 122.1, 118.9, 115.8 (d, J = 25), 63.2, 45.7, 14.1.  
 HR-MS (ESI-TOF) m/z: [M+ H] + calcd for [C18H15FN3O3]
+ 340.1092; Found: 340.1093.  
 
1-(2-methyl-5-(4-nitrophenyl)oxazol-4-yl)pyrrolidin-2-one (50s): 
Physical state  : Light yellow solid 
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Yield   :78% 
Mp   : 166-168 ˚C 
IR (MIR-ATR, 4000–600 cm-1) νmax = 3258, 3049, 2923, 2883, 2513, 1670, 1526, 1407, 
1347, 1322, 1265, 1220, 1185, 1133, 877, 821, 790, 679, 611. 
1H NMR (400 MHz, CDCl3): δ 8.38 - 8.27 (m, 2H), 8.26 - 8.11 (m, 2H), 7.33 (1H, d, J = 6.8 
Hz), 6.80 (1H, d, J = 6.8 Hz), 3.50 (1H, dt, Ja = 6.4 and Jb = 8.6 Hz), 3.39 (1H, dt, Ja = 5.9 
and Jb = 8.8 Hz), 2.36 - 2.26 (m, 2H), 2.12 (s, 3H), 2.09 - 1.91 (m, 3H). 
13C{1H}NMR (100 MHz, CDCl3): δ 191.6, 175.5, 170.2, 150.7, 138.6, 129.7, 123.9, 60.6, 
44.6, 30.3, 23.0, 18.3. 
 
(2-(4-nitrophenyl)-2-oxo-1-(2-oxopyrrolidin-1-yl)ethyl)acetamide (50s’): 
Physical state  : White solid 
Yield   :38% 
Mp   : 184-186 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3111, 2924, 2898, 1696, 1598, 1577, 1512, 1416, 
1326, 1267, 1222, 1175, 1036, 852, 689, 644. 
1H NMR (400 MHz, CDCl3): δ 8.18 - 8.34 (m, 2H) 7.56 - 7.71 (m, 2H) 3.82 - 4.00 (m, 2H) 
2.56 - 2.72 (m, 2H) 2.54 (s, 3H) 2.19 - 2.37 (m, 2H). 
13C{1H} NMR (100 MHz, CDCl3): δ 174.4, 160.7, 146.6, 140.0, 133.7, 125.4, 123.9, 48.6, 
31.2, 19.0, 14.3.  
 
1-(2-(tert-butyl)-5-(4-nitrophenyl)oxazol-4-yl)pyrrolidin-2-one (50t):  
Physical state  : Yellow solid 
Yield   :32% 
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Mp   : 168-170 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3215, 2975, 2940, 1520, 1661, 1523, 1345, 1284, 
1198, 810, 780, 729, 690. 
1H NMR (400 MHz, CDCl3): δ 8.28 - 8.38 (m, 2H) 8.19 - 8.27 (m, 2H) 7.39 (1H, d, Ja = 6.36 
Hz) 6.78 (1H, d, Ja = 6.36 Hz) 3.24 - 3.45 (m, 2H) 2.23 - 2.44 (m, 2H) 1.91 - 2.09 (m, 2H) 
1.23 (s, 9H). 
13C{1H} NMR (100 MHz, CDCl3): δ 191.8, 178.5, 175.6, 150.8, 138.5, 129.8, 123.9, 60.7, 
44.3, 39.0, 30.4, 27.6, 27.4, 18.3. 
 
N-(2-(4-nitrophenyl)-2-oxo-1-(2-oxopyrrolidin-1-yl)ethyl)pivalamide (50t’): 
Physical state  : Viscous liquid 
Yield   :78% 
IR (MIR-ATR, 4000–600 cm-1) νmax = 3111, 2974, 2932, 1709, 1599, 1514, 1413, 1337, 
1265, 1194, 1110, 1021, 853, 756, 634. 
1H NMR (400 MHz, CDCl3): δ 8.28 - 8.21 (m, 2H), 7.68 - 7.58 (m, 2H), 3.96 (2H, t, J = 7.1 
Hz), 2.67 - 2.57 (m, 2H), 2.29 (2H, quin, J = 7.6 Hz), 1.44 (s, 9H). 
13C{1H} NMR (100 MHz, CDCl3): δ 174.2, 170.3, 146.5, 139.4, 134.0, 133.5, 125.4, 123.9, 
48.6, 34.1, 31.3, 28.5, 18.8.   
 
1-(4-oxo-2-phenyl-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one (56a): 
Physical state  : White solid 
Yield   :85% 
Mp   : 222-225 ˚C 
 IR (MIR-ATR, 4000–600 cm-1): νmax = 3057, 2957, 1737, 1702, 1633, 1495, 1401, 1255, 
1161, 1116, 1095, 958, 834, 756, 731, 690. 
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 1H NMR (400 MHz, CDCl3): δ 7.93 (dd, J = 1.0, 7.8 Hz, 1H), 7.82 - 7.76 (m, 2H), 7.56 - 
7.33 (m, 6H), 3.86 (br. s., 2H), 2.66 (t, J = 8.1 Hz, 2H), 2.32 (quin, J = 7.5 Hz, 2H). 
 13C{1H} NMR (100 MHz, CDCl3): δ 176.5, 156.8, 156.0, 152.8, 150.9, 131.1, 129.5, 129.0, 
128.2, 125.4, 124.7, 120.7, 118.2, 117.4, 112.5, 109.3, 49.8, 30.9, 19.4.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C21H16NO4]
+ 346.1074; Found 346.1065. 
 
1-(2-(4-fluoro-3-methylphenyl)-4-oxo-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one 
(56b): 
Physical state  : White solid 
Yield   :81% 
Mp   : 270-273 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3055, 2923, 2889, 1739, 1698, 1635, 1506, 1438, 
1413, 1262, 1238, 1119, 1042, 963, 897, 816, 760, 721, 635. 
 1H NMR (400 MHz, CDCl3): δ 7.94 (dd, J = 1.0, 7.8 Hz, 1H), 7.67 - 7.60 (m, 1H), 7.59 - 
7.51 (m, 2H), 7.47 - 7.42 (m, 1H), 7.41 - 7.34 (m, 1H), 3.86 (br. s., 2H), 2.77 - 2.51 (m, 2H), 
2.40 - 2.34 (m, 3H), 2.34 - 2.21 (m, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 176.5, 163.1, 160.6, 156.8, 155.9, 152.7, 150.4, 131.1, 
128.9 (d, J = 6), 125.9 (d, J = 18), 125.0, 124.9, 124.7, 124.2 (d, J = 3), 120.6, 117.6, 117.4, 
116.0, 115.7 (d, J = 23), 112.5, 109.3, 49.8, 30.9, 19.4, 14.8, 14.8. 
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C22H17FNO4]
+ = 378.1136; Found 378.1128. 
 
1-(2-(4-fluorophenyl)-4-oxo-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one (56c):  
Physical state  : Light Yellow solid 
Yield   :83% 
Mp   : 268-271 ˚C 
  
136 
 
IR (MIR-ATR, 4000–600 cm-1) νmax = 3067, 2889, 1730, 1629, 1604, 1503, 1440, 1406, 
1322, 1257, 1225, 1159, 1115, 1029, 959, 894, 833, 756, 724, 682, 622, 565, 516. 
1H NMR (400 MHz, CDCl3): δ 7.92 (dd, J = 1.5, 7.8 Hz, 1H), 7.81 - 7.73 (m, 2H), 7.54 (ddd, 
J = 1.5, 7.2, 8.4 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.41 - 7.33 (m, 1H), 7.21 - 7.11 (m, 2H), 
3.86 (br. s., 2H), 2.75 - 2.56 (m, 2H), 2.32 (quin, J = 7.5 Hz, 2H). 
 13C{1H}NMR (100 MHz, CDCl3): δ 176.6, 164.4, 161.9, 156.8, 156.0, 152.8, 150.1, 131.2, 
127.6 (d, J = 9), 124.8, 124.5 (d, J = 4), 120.6, 117.9, 117.4, 116.4 (d, J = 22), 112.4, 109.2, 
49.9, 30.8, 19.4.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C21H15FNO4]
+ 364.0980; Found 364.0976.   
1-(2-(3,4-dimethoxyphenyl)-4-oxo-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one (56d): 
Physical state  : Light brown solid 
Yield   : 82% 
Mp   : 253-255 ˚C 
  IR (MIR-ATR, 4000–600 cm-1) νmax = 3747, 3673, 3614, 3055, 2308, 2134, 1741, 1701, 
1649, 1540, 1515, 1458, 1419, 1263, 1144, 1026, 965, 896, 730, 702, 559. 
 1H NMR (400 MHz, CDCl3): δ 7.95 (dd, J = 1.5, 7.8 Hz, 1 H), 7.54 (dt, J = 1.5, 7.8 Hz, 1 H), 
7.45 (d, J = 7.8 Hz, 1 H), 7.41 - 7.35 (m, 2 H), 7.34 (d, J = 2.0 Hz, 1 H), 6.97 (d, J = 8.8 Hz, 
1 H), 3.95 (d, J = 3.9 Hz, 7 H), 2.66 (br. s., 2 H), 2.31 (br. s., 2 H), 1.66 (br. s., 2 H). 
13C{1H} NMR (100 MHz, CDCl3): δ 176.5, 156.9, 155.6, 152.7, 151.2, 150.2, 149.2, 130.9, 
124.7, 120.9, 120.6, 119.0, 117.4, 116.8, 112.6, 111.5, 109.4, 108.7, 56.0, 56.0, 49.9, 30.9, 
19.5. 
 HR-MS (ESI-TOF) m/z: [M+ H] + calcd for [C23H20NO6]
 + 406.1285; Found 406.1286. 
 
1-(2-(4-methoxyphenyl)-4-oxo-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one (56e):  
Physical state  : Pale Yellow solid 
Yield   :78% 
Mp   : 253-255 ˚C 
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IR (MIR-ATR, 4000–600 cm-1): νmax = 2961, 2840, 1738, 1706, 1609, 1570, 1511, 1440, 
1401, 1305, 1255, 1176, 1117, 1034, 959, 835, 757, 687. 
1H NMR (400 MHz, CDCl3): δ 7.92 (dd, J = 1.5, 7.8 Hz, 1H), 7.76 - 7.70 (m, 2H), 7.53 (ddd, 
J = 2.0, 7.1, 8.6 Hz, 1H), 7.44 (d, J = 7.8 Hz, 1H), 7.40 - 7.33 (m, 1H), 7.03 - 6.94 (m, 2H), 
4.00 - 3.70 (m, 5H), 2.65 (t, J = 7.8 Hz, 2H), 2.31 (t, J = 7.3 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 160.5, 155.5, 152.7, 151.2, 130.8, 127.1, 124.7, 120.9, 
120.5, 117.4, 116.6, 114.5, 112.7, 109.4, 55.4, 49.9, 30.9, 19.4. 
HR-MS (ESI-TOF) m/z: [M+Na]+ calcd for [C22H17NO5]
+ 398.0999; Found: 398.1002. 
 
1-(4-oxo-2-(4-(trifluoromethyl)phenyl)-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one 
(56f): 
Physical state  : White solid 
Yield   :85% 
Mp   : 238-241 ˚C 
IR (MIR-ATR, 4000–600 cm-1) : νmax = 2889, 1976, 1740, 1703, 1625, 1506, 1442, 1409, 
1319, 1253, 1164, 1115, 1066, 1022, 956, 893, 843, 756, 690, 596. 
 1H NMR (400 MHz, CDCl3): δ 7.96 (dd, J = 1.0, 7.8 Hz, 1H), 7.93 - 7.87 (m, J = 8.3 Hz, 
2H), 7.78 - 7.69 (m, J = 8.3 Hz, 2H), 7.63 - 7.52 (m, 1H), 7.49 - 7.33 (m, 2H), 3.90 (br. s., 
2H), 2.67 (t, J = 7.8 Hz, 2H), 2.35 (quin, J = 7.5 Hz, 2H). 
 13C{1H}NMR (100 MHz, CDCl3): δ 176.4, 156.7, 156.6, 152.9, 149.2, 131.6, 131.4, 131.1, 
130.7, 126.0 (d, J = 11), 125.1, 124.9, 122.4, 120.8, 120.1, 117.5, 112.3, 109.3, 49.8, 30.8, 
19.5.  
HR-MS (ESI-TOF) m/z: [M+ Na]+ calcd for [C22H14F3NNaO4]
+ 436.0767; Found 436.0765. 
 
1-(7-methoxy-4-oxo-2-phenyl-4H-furo[3,2-c]chromen-3-yl)pyrrolidin-2-one (56g):  
Physical state  : White solid 
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Yield   :75% 
Mp   : 190-193 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3061, 2934, 2846, 1735, 1633, 1603, 1495, 1460, 
1408, 1372, 1330, 1256, 1198, 1160, 1121, 1027, 969, 946, 838, 766, 693, 634, 570. 
1H NMR (400 MHz, CDCl3): δ 7.83 (d, J = 8.3 Hz, 1H), 7.79 - 7.74 (m, 2H), 7.50 - 7.44 (m, 
2 H), 7.42 - 7.36 (m, 1H), 6.99 - 6.92 (m, 2H), 3.89 (s, 3H), 3.89 - 3.70 (m, 2H), 2.71 - 2.61 
(m, 2 H), 2.32 (t, J = 7.6 Hz, 2H). 
13C{1H}NMR (100 MHz, CDCl3): δ 176.5, 162.3, 157.1, 156.8, 154.6, 149.9, 129.2, 129.0, 
128.3, 125.3, 121.7, 118.0, 113.1, 106.8, 106.0, 101.4, 55.8, 49.8, 30.9, 19.4.  
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C22H17FNO5]
+ 376.1179; Found 376.1178. 
 
1-(2-(4-fluoro-3-methylphenyl)-7-methoxy-4-oxo-4H-furo[3,2-c]chromen-3-
yl)pyrrolidin-2 one (56h):  
Physical state  : White solid 
Yield   :86% 
Mp   : 204-207 ˚C 
IR (MIR-ATR, 4000–600 cm-1: νmax = 3633, 2933, 2886, 1734, 1699, 1635, 1608, 1503, 
1460, 1420, 1337, 1249, 1161, 1114, 1026, 973, 945, 835, 766, 720, 696, 623, 552. 
1H NMR (400 MHz, CDCl3): δ 7.82 (d, J = 8.8 Hz, 1H), 7.59 (dd, J = 1.5, 7.3 Hz, 1H), 7.57 - 
7.50 (m, 1H), 7.08 (t, J = 8.8 Hz, 1H), 6.98 - 6.91 (m, 2H), 3.89 (s, 3H), 3.88 - 3.79 (m, 2H), 
2.74 - 2.49 (m, 2H), 2.34 (d, J = 1.5 Hz, 3H), 2.33 - 2.26 (m, 2H). 
13C{1H} NMR (100 MHz, CDCl3): δ 176.4, 162.9, 162.3, 160.4, 157.1, 156.6, 154.6, 149.4, 
128.7 (d, J = 6), 125.8, 125.7, 124.8 (d, J = 8), 124.3 (d, J = 3), 121.2, 117.5, 115.9 (d, J = 
23), 113.1, 106.8, 105.9, 101.4, 55.8, 49.8, 30.9, 19.4, 14.8, 14.7.  
HR-MS (ESI-TOF) m/z: [M+ H] + calcd for [C23H19FNO5]
 + 408.1242; Found 408.1247. 
 
1-(1-hydroxy-2-oxo-2-phenylethyl)pyrrolidin-2-one (49): 
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Physical state  : White solid 
Yield   :96% 
Mp   : 98-101 ˚C 
IR (MIR-ATR, 4000–600 cm-1) : νmax = 3225, 3074, 2959, 2883, 1692, 1668, 1594, 1491, 
1417, 1352, 1265, 1233, 1177, 1116, 1024, 1000, 963, 850, 798, 756, 683, 616, 567, 535. 
1H NMR (400 MHz, CDCl3): δ  8.13 - 8.05 (m, 2H), 7.69 - 7.62 (m, 1H), 7.55 - 7.47 (m, 2H), 
6.69 (d, J = 6.8 Hz, 1H), 4.69 (d, J = 6.8 Hz, 1H), 3.48 (dt, J = 6.1, 8.9 Hz, 1H), 2.86 (dt, J = 
5.1, 8.9 Hz, 1H), 2.45 (ddd, J = 7.1, 9.7, 17.0 Hz, 1H), 2.39 - 2.26 (m, 1H), 2.08 - 1.95 (m, 
1H), 1.92 - 1.78 (m, 1H). 
13C{1H}NMR (100 MHz, CDCl3): δ 195.9, 175.4, 135.0, 131.9, 129.1, 129.0, 77.4, 77.1, 
76.7, 73.3, 41.3, 30.9, 17.8.   
HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C12H14NO3]
+ 220.0968; Found 220.0969. 
 
1-(2-oxo-1,2-diphenylethyl)pyrrolidin-2-one (57):  
Physical state  : Pale Yellow solid 
Yield   :78% 
Mp   : 104-106 ˚C 
IR (MIR-ATR, 4000–600 cm-1): νmax = 3747, 3689, 3673, 3649, 3614, 3565, 3061, 2978, 
2891, 1676, 1596, 1579, 1520, 1450, 1416, 1362, 1268, 1206, 1100, 1076, 1030, 934, 854, 
794, 762, 743, 697, 635, 590, 555. 
1H NMR (400 MHz, CDCl3): δ  7.96 - 7.87 (m, 2 H), 7.52 - 7.45 (m, 1 H), 7.41 - 7.31 (m, 5 
H), 7.30 - 7.24 (m, 2 H), 6.84 (s, 1 H), 3.81 (dt, J = 5.9, 8.8 Hz, 1 H), 2.92 (dt, J = 5.4, 9.0 
Hz, 1 H), 2.57 - 2.36 (m, 2 H), 2.16 - 2.03 (m, 1 H), 1.97 - 1.83 (m, 1 H). 
13C{1H}NMR (100 MHz, CDCl3): δ 196.5, 175.2, 135.0, 134.5, 133.4, 129.4, 129.2, 129.0, 
128.6, 77.4, 77.1, 76.7, 60.7, 45.2, 31.1, 18.3.  
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HR-MS (ESI-TOF) m/z: [M+ H]+ calcd for [C18H18NO2]
+ 280.1332; Found: 280.1326. 
  
141 
 
 
 
 
 
 
 
 
 
 
 
 
Representative 1H, 13C NMR spectral Copies  
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1H NMR (400 MHz) spectrum of compound 50a in CDCl3 
180 160 140 120 100 80 60 40 20 0
1
7
5
.2
0
1
5
9
.1
9
1
4
3
.0
2
1
3
0
.5
3
1
2
8
.7
2
1
2
8
.2
8
1
2
7
.5
4
1
2
4
.8
9
7
7
.3
7
7
7
.0
6
7
6
.7
4
4
8
.7
9
3
1
.1
4
1
9
.0
1
1
4
.2
9
 
13C NMR (100 MHz) spectrum of compound 50a in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50b in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50b in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50c in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50c in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50d in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50d in CDCl3 
 
  
146 
 
10 9 8 7 6 5 4 3 2 1 0
Chemical Shift (ppm)
2.242.142.181.051.062.151.132.130.971.01
1
0
.1
0
8
.4
6
8
.4
5
8
.4
5
8
.2
8
8
.2
6
8
.0
4
8
.0
3
8
.0
2
8
.0
1
7
.9
2
7
.6
5
7
.6
3
7
.2
6
4
.0
7
4
.0
6
4
.0
4
2
.7
0
2
.6
9
2
.6
8
2
.6
6
2
.4
1
2
.3
9
2
.3
7
2
.3
5
2
.3
3
 
1H NMR (400 MHz) spectrum of compound 50e in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50e in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50f in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50f in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50g in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50g in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50h in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50h in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50i in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50i in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50j in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50j in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50k in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50l in CDCl3 
 
180 160 140 120 100 80 60 40 20 0
Chemical Shift (ppm)
1
7
4
.9
0
1
6
7
.5
1
1
6
2
.5
1
1
6
0
.0
4
1
5
4
.5
8
1
4
3
.3
9
1
3
0
.3
8
1
2
8
.6
3
1
2
8
.5
8
1
2
5
.4
4
1
2
5
.2
6
1
2
4
.7
0
1
2
4
.6
1
1
2
3
.2
8
1
2
3
.2
4
1
1
5
.5
5
1
1
5
.3
1
7
7
.3
8
7
7
.0
7
7
6
.7
5
5
2
.7
5
4
8
.7
2
3
4
.6
6
3
1
.1
1
1
8
.9
6
1
4
.6
7
1
4
.6
4
 
13C NMR (100 MHz) spectrum of compound 50l in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50m in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50n in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50o in DMSO-D6 
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1H NMR (400 MHz) spectrum of compound 50p in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50q in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50r in DMSO-D6 
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1H NMR (400 MHz) spectrum of compound 50s in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50s in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50s’ in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50s’ in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50t in CDCl3 
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13C NMR (100 MHz) spectrum of compound 50t in CDCl3 
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1H NMR (400 MHz) spectrum of compound 50t’ in CDCl3 
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1H NMR (400 MHz) spectrum of compound 56a in CDCl3 
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13C NMR (100 MHz) spectrum of compound 56a in CDCl3 
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1H NMR (400 MHz) spectrum of compound 56b in CDCl3 
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1H NMR (400 MHz) spectrum of compound 56c in CDCl3 
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1H NMR (400 MHz) spectrum of compound 56d in CDCl3 
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1H NMR (400 MHz) spectrum of compound 56e in CDCl3 
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1H NMR (400 MHz) spectrum of compound 56h in 
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13C NMR (100 MHz) spectrum of compound 56h in CDCl3 
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1H NMR (400 MHz) spectrum of compound 49 in CDCl3 
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1H NMR (400 MHz) spectrum of compound 57 in CDCl3 
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